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Abnormal leukocyte adhesion (i.e. leukostasis) to retinal vascular endothelial cells occurs in early 
diabetes (2)6). The processes of leukostasis have been clearly demonstrated in the vascular endothelium 
of patients with diabetes. In non-proliferative DR, clinical outcomes are manifested by excessive 
permeability from inflammatory progression leading to iBRB disruption (6), endothelial cell damage 
and widespread capillary nonperfusion (2, 172). Diabetes promotes vascular leakage in DR by 
upregulation of adhesion molecules.  Moreover, many of the pathological changes in NPDR are 
related to abnormalities in retinal blood flow (39, 97, 99). Studies have shown that specific circulating 
markers of inflammatory activity and endothelial dysfunction are associated with clinical signs of 
diabetic retinopathy (121, 172). However, few have found an association between circulating levels of 
inflammatory and endothelial dysfunctional markers and abnormal retinal hemodynamics in patients 
with non-proliferative DR.  
 
The specific aims of this thesis are as follows: 
Chapter 3: To correlate baseline levels of inflammatory and endothelial dysfunction markers and 1) 
baseline retinal arteriolar hemodynamics and 2) any disturbance in retinal hemodynamics over 6-
month time in terms of vessel diameter, blood velocity, maximum-to-minimum velocity ratio and 
volumetric flow. 
Chapter 4: To correlate circulating levels of inflammatory and endothelial dysfunction markers and 
1) baseline vascular reactivity and 2) any disturbance in vascular reactivity after 6-month time in 
terms of vessel diameter, blood velocity, maximum-to-minimum velocity ratio and volumetric flow in 






Chapter 3: Diabetes subjects were stratified into either mild-to-moderate (Group 2) or moderate-
to-severe (Group 3) NPDR based on their retinopathy status. Age-matched non-diabetics were 
recruited as controls (Group 1). Forearm blood sample was collected to determine baseline levels 
of inflammatory and endothelial dysfunctional markers. At visit 1, baseline retinal 
hemodynamics was acquired using Canon Laser Blood Flowmeter. Patients returned for a visit 2 
(6 month follow-up visit) and retinal hemodynamics was reassessed. Baseline levels of 
inflammatory and endothelial dysfunctional markers compared between groups and correlated 
with both baseline and change in retinal hemodynamic parameters over 6-month time.  
 
Chapter 4: Diabetes subjects were stratified into either mild-to-moderate NPDR or moderate-to-
severe NPDR based on their retinopathy status. Age-matched non-diabetics were recruited as 
controls. At visit 1, forearm blood sample was collected to determine levels of inflammatory and 
endothelial dysfunctional markers and baseline vascular reactivity response was acquired.  
Retinal blood flow data was acquired while subjects breathed air. Retinal blood flow 
measurements were then acquired after exposure to isocapnic hyperoxic stimuli. At visit 2 (6 
month follow-up), retinal vascular reactivity was reassessed. Baseline levels of inflammatory and 
endothelial dysfunctional markers compared between groups and correlated with both magnitude 
of baseline and change in vascular reactivity in terms of retinal hemodynamics.  
 
Results 
Chapter 3: Maximum-to-minimum velocity ratio (max: min) was found to be significantly elevated 
in the group 3 compared to group 1 at baseline (0.72 vs. 0.49, after Bonferroni correction P<0.01). 
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Both sICAM-1 and sE-selectin were significantly elevated as a function of group (ANOVA p=0.02 
and p=0.04).  A post hoc Bonferroni test showed that Group 3 had significantly higher in both 
sICAM-1 and sE-selectin levels compared to Group 1 (234.0 vs. 151.5 ng/ml, P=0.02 and 53.4 vs. 
27.6 ng/ml, P<0.01, respectively). Hemoglobin A1c was significantly elevated across the groups 
(ANOVA p<0.01). A post hoc Bonferroni test showed that Group 3 had significantly higher 
hemoglobin A1c level compared to Group 1 (7.9 vs. 5.6 % , P<0.01). There were no significant 
associations found between baseline markers of inflammation and baseline retinal hemodynamics 
across all groups. The Δ velocity was correlated with the baseline sICAM-1 (r=0.42, p=0.02) and A1c 
levels (r=0.37, p=0.04) in patients with NPDR. After adjustment for all other variables (A1c, hsCRP 
and vWF), Δ velocity, sICAM-1 and A1c were found not to be reliable predictors of baseline retinal 
hemodynamics.  
 
Chapter 4: There were no significant differences in magnitude of retinal vascular reactivity in 
hemodynamic parameters between groups at visit 1 or visit 2. Over 6 months time, compliance was 
found to be significantly reduced in patients of Group 3 compared to Group 2 (-0.4 vs. 0.1, t-test 
p<0.01).  Both sICAM-1 and sE-selectin were significantly elevated as a function of group (ANOVA 
p=0.02 and p<0.01).  A post hoc Bonferroni test showed that Group 3 had significantly higher in both 
sICAM-1 and sE-selectin levels compared to Group 1 (243.4 vs. 157.3ngml, P<0.01 and 57.0 vs. 29.3 
ng/ml, P<0.01, respectively).  Hemoglobin A1c was significantly elevated across the groups 
(ANOVA p<0.01). A post hoc Bonferroni test showed that Group 3 had significantly higher 
hemoglobin A1c level compared to Group 1 (8.8 vs. 5.6 % , P<0.01). Baseline VR in blood velocity 
weakly correlates with sE-selectin (r=0.31, p=0.04) across all groups while sVCAM-1 was associated 
with VR in terms of blood flow (r=-0.62, p<0.01) in patients with mild-to-moderate NPDR. The ∆ 
blood flow after 6 months was found to be weakly associated with sE-selectin (r=0.46, p=0.03) across 
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all groups. Finally, the ∆ blood velocity after 6 month time was found to be moderately correlated 
with baseline vWF Ag level (r=-0.78, p=0.02). Multiple regression analysis found that vascular 




Chapter 3: We found weak associations between circulating markers and baseline or the disturbance 
in retinal hemodynamics after 6 months time. Overall, we found both an increase in rigidity of the 
arteriolar circulation and elevated inflammatory adhesion markers (sICAM-1 and sE-selectin) within 
the same population sample. Change in velocity over the follow-up period was correlated with 
sICAM-1 and A1c levels in patients with NPDR but the level of association was such that neither 
sICAM-1 nor A1c proved to reliably predict retinal hemodynamics. 
 
Chapter 4: We demonstrated two important characteristics in early NPDR; 1) a disturbance in 
vascular reactivity in terms of compliance and 2) an increase in systemic markers of inflammation 
were found in patients with NPDR. Although systemic markers of vascular inflammation and 
endothelial dysfunction are not predictive of hemodynamic parameters, our study found moderate 
associations between baseline and disturbances in VR after 6 months time. Therefore, there is 








I would like to express my sincerest gratitude to my supervisor, Dr. Chris Hudson, for his mentorship 
and support throughout my graduate years. I appreciate the time, knowledge and patience that you 
have so very generously given to me. I would also like to thank my thesis committee members Dr. 
John Flanagan and Dr. Wai-Ching Lam for offering their unique perspectives and helpful advice on 
my thesis work. 
 
I would also like to acknowledge Erin Harvey for lending her invaluable assistance with 
statistical analysis.  
 
I would also like to thank all of my colleagues of the Retina Research Group, especially Tien Wong, 
Olena Puzyeyeva, Jenna Adleman, Jasleen Jhajj, Drs. Ayako Anraku, Subha Venkataraman, Kit 
Guan, and Patricia Rose for their assistance and for sharing this experience with me. You have each 
been instrumental in this accomplishment and I am privileged to work with such a brilliant group of 
individuals.  
 
Of course, this achievement could not be possible without the contributions of all the volunteers in the 
study. Thank you to all the participants in the study for their generous contribution of time, patience 
and understanding to retinal physiology. They have made my work much more enjoyable and their 
participation has greatly enriched my experiences as a graduate student.  
 
Finally, I would like to thank my family and friends for their faith and encouragement throughout this 
endeavour. I am fortunate for such an excellent support network of people whom I can rely upon. 
 
 viii 
My graduate studies have been funded by the Canadian Institute of Health Research (CIHR) 





I dedicate my work to my brilliant husband Tyson, who has encouraged me to persevere and has 
always inspired me to chase my dreams.  
 
To my parents Ken and Anne Khuu, the strongest, most selfless, hard working people a child is 
blessed to have. Thank you for believing in me.  
 



















Table of Contents 
AUTHOR'S DECLARATION ............................................................................................................... ii 
Abstract ................................................................................................................................................. iii 
Acknowledgements .............................................................................................................................. vii 
Dedication ............................................................................................................................................. ix 
Table of Contents ................................................................................................................................... x 
List of Figures ..................................................................................................................................... xiii 
List of Tables ...................................................................................................................................... xiv 
List of Abbreviations .......................................................................................................................... xvi 
List of Equations ................................................................................................................................ xvii 
Chapter 1 Literature Review: Retinal Blood Flow ................................................................................ 1 
1.1 The Anatomy of Retinal Blood Supply ........................................................................................ 1 
1.1.1 Retinal Microvascular Arrangement ..................................................................................... 1 
1.1.2 The Choroidal Microvascular Arrangement ......................................................................... 2 
1.1.3 Retinal Barriers ..................................................................................................................... 4 
1.2 Structure and Function of Retinal Vessels ................................................................................... 7 
1.2.1 General Structure of the Blood Vessels ................................................................................ 7 
1.2.2 The Retinal Microvasculature ............................................................................................... 9 
1.3 Blood Flow Dynamics ............................................................................................................... 12 
1.3.1 Poiseuille’s Principal of Laminar Flow............................................................................... 13 
1.3.2 Blood Flow Regulatory Mechanisms .................................................................................. 16 
1.4 Blood Flow Regulation in the Retina ......................................................................................... 17 
1.4.1 Autoregulation in Retinal Blood Flow ................................................................................ 17 
1.5 Quantification of Retinal Blood Flow ........................................................................................ 25 
1.5.1 The Doppler Principle ......................................................................................................... 26 
1.5.2 Laser Doppler Velocimetry ................................................................................................. 27 
1.5.3 Bidirectional Laser Velocimetry ......................................................................................... 28 
1.5.4 Canon Laser Blood Flowmeter ........................................................................................... 30 
1.6 Retinal Hemodynamic Disturbance in Diabetic Retinopathy .................................................... 33 
1.6.1 Diabetic Retinopathy........................................................................................................... 33 
1.6.2 Clinical Presentation of Diabetic Retinopathy .................................................................... 33 
1.6.3 Retinal Hemodynamics in Patients with Diabetes .............................................................. 34 
 
 xi 
1.6.4 Loss of Compliance in patients with increasing severity of NPDR .................................... 35 
1.6.5 Vascular Reactivity in Patients with Diabetes ..................................................................... 35 
1.7 Inflammation and Endothelial Dysfunction in NPDR ................................................................ 37 
1.7.1 Vascular Inflammation in Diabetes ..................................................................................... 37 
1.7.2 Pathogenesis of DR Mechanisms; Retinal Leukostasis ....................................................... 38 
1.7.3 Leukocyte-Endothelial Interaction ...................................................................................... 38 
1.7.4 Circulating Markers of Inflammation .................................................................................. 40 
1.7.5 Endothelial Cell Dysfunction in Type 2 Diabetes ............................................................... 44 
Chapter 2 Rationale .............................................................................................................................. 46 
2.1 Aims ........................................................................................................................................... 48 
2.2 Relevance ................................................................................................................................... 50 
Chapter 3 .............................................................................................................................................. 51 
Baseline Retinal Hemodynamics, Systemic Markers of Vascular Inflammation and Endothelial 
Dysfunction in Type 2 Diabetes ........................................................................................................... 51 
3.1 Overview .................................................................................................................................... 51 
3.2 Introduction ................................................................................................................................ 53 
3.3 Materials and Methods ............................................................................................................... 55 
3.3.1 Sample ................................................................................................................................. 55 
3.3.2 Methodology ....................................................................................................................... 56 
3.3.3 Procedures ........................................................................................................................... 58 
3.4 Analysis ...................................................................................................................................... 59 
3.4.1 Blood Flow Analysis ........................................................................................................... 59 
3.5 Results ........................................................................................................................................ 60 
3.5.1 Baseline, follow-up and change (Δ) over 6 months time in retinal hemodynamic parameters
 ...................................................................................................................................................... 60 
3.5.2 Baseline inflammatory and endothelial dysfunction marker levels ..................................... 66 
3.5.3 Bivariate Pearson correlations between baseline markers of inflammation/endothelial 
dysfunction and baseline retinal hemodynamics measurements .................................................. 69 
3.5.4 Pearson correlation between baseline levels of inflammatory/endothelial dysfunction 
markers and change (Δ) in retinal hemodynamics over 6 month time ......................................... 70 
3.6 Discussion .................................................................................................................................. 73 
 
 xii 
Chapter 4 Retinal Vascular Reactivity and Systemic Markers of Vascular Inflammation, Endothelial 
Dysfunction in Type 2 Diabetes........................................................................................................... 78 
4.1 Overview .................................................................................................................................... 78 
4.2 Introduction ................................................................................................................................ 80 
4.3 Materials and Methods ............................................................................................................... 82 
4.3.1 Sample ................................................................................................................................. 82 
4.3.2 Methodology ....................................................................................................................... 84 
4.3.3 Procedures ........................................................................................................................... 85 
4.4 Analysis...................................................................................................................................... 87 
4.4.1 Blood Flow Data ................................................................................................................. 87 
4.4.2 Evaluation of disturbance in vascular reactivity over 6 months ......................................... 87 
4.4.3 Statistical Analysis .............................................................................................................. 88 
4.5 Results ........................................................................................................................................ 88 
4.5.1 Baseline (visit 1) and follow-up (visit 2) vascular reactivity response ............................... 89 
4.5.2 Change in vascular reactivity response (ΔVR) over 6 month time ..................................... 93 
4.5.3 Baseline levels of inflammation and endothelial dysfunction markers ............................... 95 
4.5.4 Relationship between baseline (visit 1) VR and baseline levels of vascular inflammation 
and endothelial dysfunction ......................................................................................................... 98 
4.5.5 Bivariate Pearson correlations between change in vascular reactivity (ΔVR) and baseline 
levels of vascular inflammation and endothelial dysfunction .................................................... 100 
4.6 Discussion ................................................................................................................................ 104 
Chapter 5 General Discussion ............................................................................................................ 110 
Appendix A ........................................................................................................................................ 114 
Isolating Markers of Inflammation (sICAM-1, sVCAM-1, and E-selectin) .................................. 114 





List of Figures 
Figure 1-1: Structure of a blood vessel   ................................................................................................... 7
Figure 1-2: A schematic diagram of laminar flow within a vessel.   ...................................................... 14
Figure 1-3: The Doppler principle   ........................................................................................................ 26
Figure 1-4: Diagrammatic representation of bidirectional laser Doppler velocimetry.   ........................ 28
Figure 1-5: Photograph of the Canon laser blood flowmeter (model 100).   .......................................... 30
Figure 1-6: A schematic diagram of increased leukocyte-endothelial cell adhesion and entrapment 
(leukostasis) in diabetic retinopathy.   .................................................................................................... 40
Figure 3-1: Baseline retinal hemodynamic parameters as a function of group.   ................................... 62
Figure 3-2: Group means at baseline and follow-up as a function of group.   ....................................... 65
Figure 3-3: Box plots of inflammatory, and endothelial dysfunction, markers as a function of group.
  .............................................................................................................................................................. 67
Figure 3-4: Box plots of hs CRP and A1c markers as a function of group.   ......................................... 68
Figure 3-5: Scatter plot of baseline sICAM-1 levels and change (Δ) velocity in 6 months time across 
patients with NPDR.   ............................................................................................................................. 72
Figure 4-1: Box plots of vascular reactivity in retinal hemodynamic parameters in response to an 
isocapnic hyperoxic stimulus a function of group at visit 1.   ................................................................ 90
Figure 4-2: Box plots of vascular reactivity in retinal hemodynamic parameters in response to an 
isocapnic hyperoxic stimulus a function of group at visit 2.   ................................................................ 92
Figure 4-3: Box plots of change in vascular reactivity (ΔVR) from visit 1 to visit 2 (6 month follow-
up) in terms of retinal hemodynamic parameters.   ................................................................................ 94
Figure 4-4: Box plots of baseline levels of inflammation and endothelial dysfunction markers as a 
function of group.   ................................................................................................................................. 96
Figure 4-5: Box plots of hs CRP and A1c markers as a function of group.   ......................................... 97
Figure 4-6: Scatter-plot of baseline vascular reactivity in blood velocity and baseline sE-selectin 
across all groups.   .................................................................................................................................. 99
Figure 4-7: Scatter plot of the change in vascular reactivity from visit 1 to visit 2 in terms of blood 




List of Tables 
Table 3-1: Demographic details of the study sample.   .......................................................................... 56
Table 3-2: Group mean retinal hemodynamic parameters at baseline visit.   ........................................ 61
Table 3-3: Group mean retinal hemodynamic parameters at follow-up visit.   ..................................... 63
Table 3-4: Magnitude of change in retinal hemodynamics from baseline to follow-up visit in patients 
with NPDR.   .......................................................................................................................................... 64
Table 3-5: Group mean and standard deviation of markers inflammation and endothelial dysfunction 
as a function of group.   ......................................................................................................................... 66
Table 3-6: Group mean and standard deviation of A1c and hs CRP as a function of group.   .............. 68
Table 3-7: Pearson correlation values (r) and statistical significance (p) between baseline levels of 
markers of inflammation/ endothelial dysfunction and baseline retinal hemodynamic parameters 
across the pooled group.   ...................................................................................................................... 69
Table 3-8: Pearson correlation values (with associated p-values) between baseline levels of 
inflammatory/endothelial dysfunction markers and Δ in retinal hemodynamic parameters in 6 months 
time among patients with NPDR in Study 1.   ....................................................................................... 71
Table 4-1: Demographic details of the baseline study sample.   ............................................................ 83
Table 4-2: Group mean vascular reactivity in terms of retinal hemodynamic parameters to a 
standardized isocapnic hyperoxic stimulus at visit 1.   .......................................................................... 89
Table 4-3: Group mean vascular reactivity (VR) in terms of retinal hemodynamic parameters to a 
standardized isocapnic hyperoxic stimulus at visit 2.   .......................................................................... 91
Table 4-4: Mean Δ vascular reactivity in terms of retinal hemodynamic parameters as a function of 
group.   ................................................................................................................................................... 93
Table 4-5: Group mean and standard deviation (SD) of markers inflammation and endothelial 
dysfunction as a function of group.   ...................................................................................................... 95
Table 4-6: Group mean and standard deviation of A1c and hs CRP as a function of group.   .............. 97
Table 4-7: Pearson correlation coefficients (r) and statistical significance (p) between markers of 
inflammation/endothelial dysfunction and baseline vascular reactivity (VR) in retinal hemodynamics 
ratio across all groups.   ......................................................................................................................... 98
Table 4-8: Pearson correlation coefficients (r) and statistical significance (p) between markers of 
vascular inflammation/endothelial dysfunction and baseline vascular reactivity in blood flow in mild-
to-moderate NPDR.   ............................................................................................................................ 100
 
 xv 
Table 4-9: Pearson correlation coefficients (r) and statistical significance (p) between markers of 
inflammation/endothelial dysfunction and Δ VR in hemodynamic parameters in patients with NPDR.
  ............................................................................................................................................................ 101
Table 4-10: Pearson correlation coefficients (r) and statistical significance (p) between Δ velocity and 
markers of inflammation/endothelial dysfunction in patients with moderate-to-severe NPDR (Group 




























List of Abbreviations 
Advanced glycation end-products (AGE); Average velocity (V
mean
); Basement membrane (BM); 
Blood flow (Q); Blood pressure (BP); Blood retinal barrier (BRB); Branch retinal vein occlusion 
(BRVO); Calcium ion concentration (Ca
2+
); Canon laser blood flowmeter (CLBF); High sensitivity 
C-reactive protein (hs CRP); Carbon dioxide (CO
2
); Central retinal artery (CRA); Clinically 
significant DME (CSDME); Diabetes control and complications trial (DCCT); Diabetic macular 
edema (DME); Diabetic retinopathy (DR); Diameter (D); Early Treatment Diabetic Retinopathy 
Study (ETDRS); Endothelial-derived contracting factors (EDCF); Endothelial-derived relaxing 
factors (EDRF); Endothelin (ET); Fractional inspired oxygen (FiO
2
); Frequency (f); Glycosylated 
hemoglobin (A1c); Internal limiting membrane (ILM); Intra-ocular pressure (IOP); Length (L); Lens 
Opacity Classification System III (LOCS III); Maximum frequency shift (Δf
max
); Maximum to 
minimum (max:min); Microaneurysms (MAs); Monocyte chemoattractant protein type 1 (MCP-1); 
Nitric oxide (NO); Oxygen (O
2
); Partial pressure of arterial carbon dioxide (PCO
2
); Partial pressure of 
arterial oxygen (PO
2
); Positive end-expiratory pressure (PEEP); Pressure gradient (ΔP); Protein 
kinase C (PKC); Proliferative diabetic retinopathy (PDR); Resistance (R); Retinal pigment epithelium 
(RPE); Smooth muscle cells (SMCs); Soluble vascular cell adhesion molecule type 1 (sVCAM-1); 
soluble intercellular adhesion molecule type 1 (sICAM-1); soluble E-selectin (sE-selectin); Tumour 
necrosis factor- alpha (TNFα); United Kingdom Prospective Study (UKPDS); Vascular endothelial 
growth factor (VEGF); Visual acuity (VA); von Willebrand factor antigen (vWF ag); von Willebrand 
factor activity (vWF act); Wall shear rate (WSR). 
 
 xvii 
List of Equations 
Equation 1-1 Ohm’s law   ....................................................................................................................... 12




Literature Review: Retinal Blood Flow 
1.1 The Anatomy of Retinal Blood Supply  
The delivery of oxygen and metabolic substrates to the retina, and the removal of waste products, is 
primarily accomplished by the inner retinal and choroidal circulatory systems.  Although the inner 
retinal and choroidal systems are both branches of the ophthalmic artery, they differ anatomically and 
functionally. 
1.1.1 Retinal Microvascular Arrangement  
Unlike most other organs, the inner retinal circulatory system is a unique end-artery microvascular 
system. Oxygenated blood travels to the eye from the aortic artery of the heart. The first two arteries 
branching from the aorta are the brachiocephalic artery, which supplies the right arm and right 
common carotid artery, and the left common carotid artery. Each of the common carotid arteries 
branch into an internal, and an external, carotid artery. The main blood supply to the orbit appears 
from the internal carotid via the ophthalmic artery (OA). Smaller vascular contributions are from the 
external carotid artery via infraorbital artery and orbital branch of the maxillary artery. The maxillary 
artery supplies the soft tissue of the orbital floor, lacrimal sac, nasolacrimal duct, and give a minor 
supply to the inferior rectus, inferior oblique, and orbicularis muscles (81). The OA runs inferior to the 
optic nerve and into the optic canal and branches into the central retinal artery (CRA), long- and 
short-posterior ciliary arteries, and the anterior ciliary arteries that also receive supply from facial 
artery (78).  
 
The central retinal artery (CRA), along side the central retina vein (CRV), supplies the inner two 
thirds of the retina (78). The CRA enters the optic nerve about 10mm behind the eyeball and appears at 
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the junction of the optic disc and the surface of the retina through the lamina cribrosa. The first 
bifurcation of the CRA occurs at this point and it branches into four major retinal vessels, each of 
which supplies one quadrant of the retina (1)78). Each of the arterioles continue to bifurcate within the 
transparent never fiber layer, supplying blood to each sector of the retina. The superior and inferior 
temporal artereioles arch above and below the macula region creating a foveal avascular zone (FAZ) 
approximately 0.4mm in diameter. This vessel free region facilitates the maximum absorption of light 
by the central photoreceptors without the disruption of a single blood vessel (43). Overall, retinal 
capillaries run parallel to the retinal nerve fiber layer. Layers of retinal capillaries are greater in 
number in the posterior pole compared to the more peripheral retina. The terminal ends of the 
arterioles and venules are linked through the retinal capillary beds. To complete the circulatory cycle, 
the central retinal venule is the site for retinal drainage via the vortex venules. This vein exits the eye 
through the optic nerve and drains into the cavernous sinusi
 
 or into the superior ophthalmic vein.  
The outer retina includes photoreceptors and bipolar cells which are avascular and primarily 
receive metabolic energy and O2 from the highly vascularized choroidal circulation (133). This tissue is 
by far the most metabolically active in the body and is therefore highly demanding of nutrients. This 
layer is separated from the inner retinal layer by the retinal pigment epithelium (RPE). With an 
apical-basal polarity, the RPE is a highly active inter-face in the transport of waste and (85) metabolites 
to and from the retina to the choroid (4).  
 
1.1.2 The Choroidal Microvascular Arrangement 
The choroidal circulation exhibits one of the highest rates of blood flow in the body. At any one time, 
more than 70 % of all the blood in the globe can be found in the capillary network of the choroid, the 
choriocapillaris. Anatomically, the choroid is a highly vascularized and pigmented to form the 
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posterior part of the uveal tract. It extends from the ora serrata to the optic nerve posteriorly. The 
choroid is attached to the sclera by strands of connective tissue and is tightly adherent to the optic 
nerve and retinal pigment epithelium. The unique structure of the choroid is important in: 1) heat 
dissipation as a result of the high flow rate generated by the high metabolic activity associated with 
phototransduction of the photoreceptors; 2) nourishment of the retinal pigment epithelium and a part 
of the retina, up to the outer aspect of the inner nuclear layer; and 3) in the establishment of 
pigmentation of the fundus (75).  
 
Blood supply to the choroidal vasculature stems from the ophthalmic artery (OA), the first branch 
of the internal carotid artery (CRA), via the medial and lateral posterior ciliary arteries. Before 
piercing the sclera, the posterior ciliary divides into a long posterior artery (LPCA). A variable 
number of short posterior arteries (SPCAs) arise separately from the OA. Together a total of 2 LPCAs 
and 15-20 SPCAs are produced. The LPCAs pierce the sclera approximately 3-4mm from the optic 
nerve and course anteriorly through the suprachoroidal space between the choroid and sclera, to a 
branch point near the ora serrata. The LPCAs supply the anterior choriocapillaries and at this point, 
each of the LPCA branches three to five times to extend posteriorly to supply the choriocapillaries 
near the equator. The SPCAs on the other hand, enter the sclera in close proximity to the ONH and 
continue only a short distance from the optic nerve. These vessels branch immediately to supply the 
posterior portion of the choriocapillaries up to the equator (68). Unlike most vascular networks in the 
body, the choroidal arteries and veins do not run parallel. Venous drainage of the choriocapillaries is 
mainly through the vortex vein system. Minor drainage occurs through the ciliary body through the 




Finally, the capillary walls in the choroid are quite different from those of the capillary walls of the 
retina. In the choriocapillaries, the walls have a thin endothelial covering with large, numerous 
fenestrations. Such fenestrations allow for high permeability to low molecular weight substances. 
This degree of permeability is necessary to maintain a high concentration of glucose at the retinal 
pigment epithelium and to permit passage of proteins involved in the supply of the retina (4). Whereas 
in the inner ret require tight endothelium that creates the inner BRB. 
 
1.1.3 Retinal Barriers 
Optimal cell function is achieved when the biological environment is tightly regulated. Just as the 
brain neurons depend stringently on controlled homeostasis, the retina although structurally different, 
relies on the barriers that prevent adverse changes affecting the composition of the nurturing blood 
and the neural architecture (4).  In both cases, this regulation is established by the cellular barriers, 
which separate functional compartments and control the transport between them; the inner and outer 
blood retinal barriers. The main structures involved, for the inner blood-retinal barrier, are the 
endothelial membrane, and for the outer blood-retinal barrier, is the retinal pigment epithelium (4). 
1.1.3.1 Inner Blood-Retinal Barrier (iBRB) 
The endothelial membrane of the inner retinal vessels is an elaborate network that separates the blood 
from the retina at the level of the vessels, termed the inner blood retinal barrier (iBRB). The structure 
and pattern of the retinal blood vessels present marked differences from those of other organs. It was 
in 1966, Shakib and Cunha-Vaz described the fundamental difference between the endothelial 
membrane of vessels with and without a barrier (157). The endothelial cells form a continuous, non-
fenestrated, “tight” monolayer of cells that line the inner retinal vessel lumen. The most outstanding 
feature of the inner retinal endothelial cells is the presence of junctional inter-endothelial structures, 
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zonulae occludens or tight junctions, areas of complete fusion of the outer leaf of the neighboring 
membrane (25). The presence of these tight junctions is to maintain an inner blood-retina barrier. The 
fusion of the endothelial membrane creates a barrier around the inner retinal vessels that is resistant to 
the leakage of blood-borne substances.  Retinal capillaries do not leak usually flourescein, glucose or 
amino acids but are highly permeable to water and lipid soluble substances such as oxygen and 
carbon dioxide (133) and small metabolic weight compounds. Interactions with glial cells such as 
astrocytes are required for the endothelial cells to develop tight junctions. Disruption of the iBRB, as 
in some pathological situations (diabetes, hypertension), can compromise the endothelial cells and 
result in lost tight junction integrity. 
1.1.3.2 Outer Blood- Retinal Barrier (oBRB) 
Within the outer retina, the retinal pigment epithelium and Bruch’s membrane complete the array of 
outer blood retinal barrier (oBRB) tissues. Together, these structures show increasing restriction to 
size and polarity of blood borne solutes, with the most permissive being the fenestrated endothelium 
of the choriocapillaris to the most stringent retinal pigment epithelium (RPE), a consequence of tight 
junctions (133).    
 
The RPE plays a central role in the oBRB and supports the function of the photoreceptors. The 
RPE is a highly polarized monolayer with an elaborate transcellular pathway system. Considered a 
“tight” epithelium, the RPE’s integrity and complexity is attributed to the partially overlapping 
intercellular junctions, the zonula adherens, tight junctions and gap junction. The RPE’s apical-basal 
polarity allows the transport of; 1) nutrients including essential amino acids and vitamin A from the 
blood to the photoreceptors and 2) removal of metabolites, extracellular fluid and ions from the 
subretinal space towards the choriocapillary bed. Trans-epithelial ion transport is responsible for the 
transport of lactic acid, the major end product of neuronal function. The accumulation of water from 
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intensive metabolic turnover requires constant removal by the glial cells from the inner retina and 
RPE from the subretinal space (133).   Although the RPE is capable of site specific functions, it 
nevertheless possesses many similar functions with endothelial barriers  (166).  
 
Bruch’s membrane (BM) carefully regulates the passage of molecules across the oBRB.  The BM 
is an elastin and collagen rich extracellular matrix that acts as a molecular sieve. This membrane has 
five distinct layers; 1) the basal lamina of the RPE 2) the inner and 3) outer collagenous layers and 4) 
the central discontinuous elastic layer and 5) the endothelium of the choriocapillaris. This 
pentilaminar BM structure forms a single function unit / complex with juxtaposition with the RPE 
and choriocapillaris and regulates the exchange of products between the retina and the general 
circulation (16). More specifically, the BM serves three primary roles; 1) regulating the diffusion of 
biomolecules between the choroid and the RPE 2) providing physical support for the RPE cell 
adhesion, migration and perhaps differentiation and 3) acting as a division barrier, restricting 
choroidal and retinal cellular migration.  Given its unique location, the BM plays a critical role in 
cell-cell communication, cellular differentiation, proliferation or migration, tissue remodeling and in 
shaping pathological processes (16)(17). Accumulating evidence suggests that properties of the BM are 
dependent on age, genetic constitution, environmental influences and disease state.  Disruption to the 
BM can lead to the onset and progression of diseases like retinitis pigmentosa and age related macular 
degeneration (16). As a result, properties of the BM are unique to each human individual and can 







There is evidence that a failure of either the iBRB or oBRB can lead to vision threatening diseases. A 
compromised blood retina barrier occurs in diseases such as diabetic retinopathy / macular edema, 
hypertensive retinopathy, sickle cell retinopathy and acquired immunodeficiency syndrome (AIDS). 
 
1.2 Structure and Function of Retinal Vessels 
1.2.1 General Structure of the Blood Vessels 
Blood vessels carry blood to and from the heart and regardless of their exact role, blood vessels have 
a comparable structural organization. Characteristically, the walls of larger blood vessels are 
composed of three layers; tunica intima, tunica media, and tunica adventitia. The tunica intima (or 
tunica interna) is the innermost layer and lines the inside of the lumen, consisting of a single layer of 
squamous endothelial cells. The endothelial layer is in direct contact with the actively moving 
erythrocytes and reduces the friction between the vessel wall and blood. The tunica media is a region 
that is largely composed of circularly arranged smooth muscle cells and sheets of elastin. Finally, the 
outermost layer is the tunica externa (or tunica adventitia) is made up of collagen fibers which 











1.2.1.1 The Arterial System 
The walls of the aorta and other large diameter arteries have relatively more elastin than smooth 
muscle layers. This allows the vessel to resist high blood pressure fluctuations by stretching during 
systole and recoiling on the blood during diastole (115). From the aorta, as the artery divides, each 
subsequent branch has a proportionately greater amount of smooth muscle to elastin. Although larger 
arterioles possess all three tunics, smaller arterioles can contain as little as a single layer of smooth 
muscle around an epithelial lining.  Generally, smooth muscle is innervated by noradrenergic fibers 
that function as constrictors and in some instances, cholinergic fibers that can dilate the vessels. 
Specifically, muscular endowed and highly flexible arterioles deliver oxygenated blood to specific 
organs and are specifically active in vasoconstriction. Whilst arterioles are the smallest of all arteries, 
they determine and regulate blood flow into the capillary bed by both vasoconstriction and 
vasodilation. 
1.2.1.2 The Capillary Bed 
Arteries divide into muscle walled arterioles (resistance vessels) and feed into capillaries (exchange 
vessels). Capillaries are the smallest blood vessel and are the location for the exchange of substances 
between the blood and the interstitial fluid.  In the simplest form, the capillary wall is made up of only 
a tunica interna consisting of a layer of endothelium and a basement membrane. The narrow lumen 
allows for a single file line of red blood cells to pass through. Generally, there are three main types of 
capillaries; continuous, fenestrated and discontinuous. In the inner retina, capillary beds are made up 
of two types; continuous and non-fenestrated capillaries. Continuous capillaries are the least 
permeable type but allow the passage of fluids, small solutes and molecules. Capillary beds are an 
interweaving network of true capillaries and meta-arterioles; channels which connect the arterioles 
and the venules at both ends of a bed. True capillaries are 5µm at the arteriole end and about 9 µm at 
the venous end. These convoluted arrays of capillaries function as exchange vessels for oxygen, 
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hormones and nutrients. To locally modulate blood flow into the capillary bed, a cuff of smooth 
muscle, called the precapillary sphincter, surrounds each capillary at the meta-arteriole (7). When the 
sphincter is dilated, the diameter of the vessel is permits red blood cells to just “squeeze” through 
capillaries in a single file. As a result, red blood cells fold into a parachute shape as a consequence of 
flow pushing at the center (115) to form a parabolic velocity profile. Overall, the structure and 
permeability of capillaries vary can differ depending on the needs of the organ. 
1.2.1.3 The Venous System 
Blood collecting from the capillary bed exits into the venular system that is very porous to allow for 
absorption of white blood cells and other fluids. The walls of the venules are only slightly thicker 
than that of capillaries and consist mainly of a layer of endothelium. Overall, veins have a thinner 
wall, very few layers of smooth muscle, thin layer of tunica externa, and have a larger lumen than 
equivalent arteries. The blood pressure in veins is low because of the relative absence of a ventricular 
contraction. Although smooth muscles are nearly non existent, considerable vasoconstriction is 
produced as a result of noradrenergic nerve fibers to the vein and also circulating vasoconstrictors 
such as endothelin-1 (127, 187). One way valves, present as folds in the tunica interna, prevent back 
flow. The presence of valves within the venous system is especially important in the extremities since 
the flow of blood is often opposed by gravity. 
1.2.2 The Retinal Microvasculature  
Hierarchal arteriolar networks differ in function and in structure. Not unlike the general network, the 
retinal microvascular circulatory system is also made up of arterioles, capillaries and venules; each 
with a unique structure and function.   The arterioles are well invested in smooth muscle cells and are 
responsible for the delivery of blood to localized tissue and also regulate the flow of blood by 
responding to myogenic, metabolic and hormonal stimuli. Capillaries have thin walls to facilitate the 
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exchange of nutrients between tissue and blood. The venules drain blood from the capillaries and 
parallel the organization of the arterioles. Structural differences allow the supply of nutrients to meet 
the specific metabolic demands of an organ under various stress conditions.  The specialized blood 
vessels of the retina are unique since it is a complex system that differs anatomically and 
physiologically.  
1.2.2.1 Retinal Arterioles 
The structure of the retinal vasculature is highly specialized since it is dependent on diameter in order 
to maintain consistent blood flow.  This is primarily accomplished because of its unique ability to 
respond to a variety of stimuli. Structurally, when compared to the same size arteries of other organs 
in the human body, arteriole branches of the central retinal artery lack an internal elastic lamina and 
gradually contain decreased layers of smooth muscle cells from the optic disk to the periphery (106). 
Direct branch arterioles of the central retinal artery are approximately ~100 to150 μm in diameter 
close to the ONH. A retinal pre-capillary arteriole has capillary dimensions (~10µm in diameter) but 
is enveloped by a single continuous layer of smooth muscle. These vessels merge seamlessly into a 
vast capillary network.  It is apparent that arterioles are uniquely suitable for flow regulation as they 
are capable of larger changes in diameter as a percentage; greater than any other vessel in the 
circulatory system. 
1.2.2.2 Retinal Capillaries 
With the advent of the electron microscope, classifying capillaries based on morphological features 
lead to the formation of functional concepts.   When the flow of blood is modulated by the upstream 
retinal arterioles, flow in the retinal capillary bed also changes. The retinal capillaries are distributed 
into two distinct layers; 1) the superficial layer that resides in the nerve fiber and ganglion cell layer 
and 2) the inner layer that is located in the inner portion of the inner nuclear layer between the inner 
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and outer plexiform layers (106). Additionally, there is a network of capillaries located superficially in 
the nerve fiber layer called the peripapillary capillaries and run along the major superotemporal and 
inferotemporal vessels. The periparillary capillaries anastomose with each other and with the deeper 
capillaries. The two distinct capillary layers run in parallel until they reach the macular region where 
they join as a single layered ring; the perimacular ring. Within the macula area, there is a blood 
vessel and capillary free zone known denoting the fovea that is 400µm in diameter (4). 
 
Histological evidence shows that the retinal capillary walls are composed of endothelial cells, 
intramural pericytes and a basement lamina (133, 134). Each capillary unit is approximately ~5-6 μm in 
diameter (4).  The endothelial cells form a continuous, non-fenestrated, monolayer that is coupled to 
neighboring endothelial cells by tight junctions, zona occludentes. The endothelial cells are oriented 
along the axis of the capillary, with cytoplasmic extensions encircling the lumen (106). Retinal 
pericytes surround the endothelium and occur in a 1:1 ratio with the endothelial cells and 
communicate via gap junctions (7).  
 
Experimental evidence has shown that pericytes possess contractile properties (90). This contractile 
property allows pericytes in the capillary (90) wall to further “fine tune” local flow of blood.  
Therefore, capillary perfusion is primarily regulated by the upstream arterioles but then also further 
modulated by the contractile pericytes that are located on the luminal wall of capillaries.  
 
Summary 
Overall, it is apparent that the structure the arteriole specifically dictates its function within the retinal 
microcirculation. The primary role of blood vessels is to regulate the flow of blood and intravascular 
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pressure. This is accomplished by changes in upstream arteriolar diameter as a result of several 
mechanisms that potentiate these changes. While arterioles regulate total blood flow to the retina, the 
capillary network, which independently contracts and further modulates the local distribution within 
the tissue.  Retinal blood flow is determined by a combination of myogenic mechanisms, the local 
demand for metabolites, the resting vascular resistance and capillary perfusion pressure in the 
capillary bed. 
 
1.3 Blood Flow Dynamics 
Blood flow is the volume of blood that flows through a certain point in the cardiovascular system 
during a specified amount of time. The underlying principles that govern the flow of fluid within a 
cylindrical tube are applicable to the movement of blood cells within a blood vessel. Specifically, the 
flow of fluid within a tube is dependent entirely on two factors; 1) the perfusion pressure between the 
two ends of the vessel and 2) the impediment of flow through a vessel, known as vascular resistance. 
Ohm’s law describes the same physical factors that govern the flow of any fluid, and are based on the 
fundamental law of physics (10).              
           
 
Equation 1-1 Ohm’s law 
 
Flow (Q) is directly related to the difference in pressure (ΔP) between the two ends of the tube and 
inversely related to the resistance (R). Within a vessel segment, there is a difference in pressure 
between two points along a given length.  This will result in a movement of blood from a high to a 
lower pressure zone. According to Ohm’s equation, the blood flow between two points is directly 
       Q = ΔP  
                R 
 




proportional to the difference in pressure between the two points (ΔP), also known as the perfusion 
pressure (assuming constant vascular resistance and blood viscosity). This force perpetuates the 
movement of blood throughout the entire body. In order to accomplish this forward movement, there 
must be a difference in blood pressure within our circulatory system.  
 
Resistance is dependent on the properties of the fluid and the tube to which it is flowing through. 
Blood pressure is the product of two separate forces. The first is created by the heart as it pumps 
blood into the arteries through the circulatory system and the other is the force that resists the 
movement of blood.  Resistance to blood flow within a vascular system is dependent on the size of 
the individual vessels (length and diameter), the arrangement of the vessel bed (series or parallel), 
physical characteristics of the blood (viscosity, laminar vs. turbulent flow) and vasoactive substances 
acting upon the vasculature. Within a tube, Ohm’s law describes the relationship between flow and 
resistance; the higher the resistance to the flow, the lower the blood flow through a vessel. 
1.3.1 Poiseuille’s Principal of Laminar Flow 
Of the mentioned factors that contribute to resistance, a change in vessel diameter is the most 
important factor in quantifying blood flow within an organ, as well as regulating arterial pressure (10).  
It was not until 1846 that the physiologist J.L.B Poiseuille combined the study of flow of liquids with 
properties of a tube and established an equation that described the relationship between pressure (P), 
flow (Q), radius (r), visocity(η) and dimensions (L) of the tube.  
 
 
Equation 1-2 Poiseuille’s Equation 
Q = ΔP π r
4
 
      8 η L 
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From this, Poiseuille’s law was derived; the rate of blood flow is directly proportional to the forth 
power of the radius (r) of the vessel(10). This illustrates that diameter plays a great role in determining 
the rate of blood flow through the vessel.  
1.3.1.1 Poiseuille’s Law of Laminar Blood Flow 
Laminar flow is the normal condition of blood flow through most of the circulatory system. This 
movement is described as concentric layers of blood moving in parallel throughout the length of a 
blood vessel. The outcome of this arrangement is that the highest velocity occurs in the center of the 
vessel, while the lowest velocity occurs along the vessel wall, often termed a parabolic velocity 
profile. Alternatively, plug flow is the simplest type of flow where all velocities are constant. When 
there is a disruption in laminar flow, the flow of blood is no longer smooth but chaotic and is known 
to be turbulent. 
 
 
Figure 1-2 A schematic diagram of laminar flow within a vessel. 
 Cross section profile of laminar flow. Concentric rings represent changing velocity, from the outside 
having zero velocity and increases as we move towards the center. b) The side profile of laminar flow. 
The highest velocity for both profiles is located in the center.  
 
Side profile  Cross section 
fil   
a) b) 




Laminar flow reduces the amount of energy that is lost to the vicious interactions between the 
layers of the blood and the walls of the vessel (10). One method of quantifying the parabolic velocity 
profile is using SDOCT Doppler. The peak or cut-off frequency shift of the scattered light produced 
by the moving erythrocytes is proportional to the maximum velocity found in the centerline flow. In 
small vessels (<40 to 60 µm in diameter), essentially all of the blood is very near to the wall and the 
central stream of rapid flowing blood does not exist.   
 
Overall, Poiseuille’s law describes the relationship between these variables based on several 
major assumptions; 1) the tube is stiff, straight, and uniform and 2) the blood behaves in a 
Newtonian manner (i.e. viscosity is non-existent such that the fluid flows freely and does not  
resist flow). That is with regard to the flow through cylindrical tubes, it will vary as a function of 
the nature of the fluid itself. This flow determining property is viscosity and is defined by 
Newton as the ratio of shear stress to the shear rate of the fluid. Lastly, 3) the flow of blood is 
laminar and steady and the velocity at the wall is zero (law of Poiseuille). However, the 
cardiovascular system differs from the rigid tubes studied by Poiseuille in that 1) the vessels of 
the human body are elastic and 2) rhythmic contractions of the heart produce pulsatile blood 
flow. Despite these limitations, Poiseuille’s equation is a useful approximation for the calculation 
of blood flow and is believed to exist in the retinal blood vessels that are 60 to 80μm in diameter 
or larger (10). 
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1.3.2 Blood Flow Regulatory Mechanisms 
Each organ within the body has an intrinsic ability to regulate the flow of blood. Mechanisms to 
regulate the blood flow are unique to each organ where some originate within the blood vessels and 
others are regulated by the central nervous system.  
Specialization of function within the walls of blood vessels allow for the regulation of blood flow. 
Two types of methods derived from walls of the blood vessels include the myogenic mechanism and 
endothelial factors. The myogenic mechanism is the intrinsic ability of the smooth muscle cells to 
respond to changes in blood pressure to maintain the demand for nutrients, particularly in small 
arteries and arterioles that supply organs. If there is a pressure increase, the smooth muscle layer 
within the vessel wall responds by vasoconstricting. If there is a decrease in pressure, the smooth 
muscles responds by vasodilation. The vascular endothelium plays an important role in the regulation 
of smooth muscle condition. Endothelial derived factors lead to vasoconstriction [by endothelin (ET-
1)] or vasodilation [by nitric oxide (NO) or prostacylcin (PGI2)], acting on vascular smooth muscle 
cells. These vasoactive agents originate via blood and exert on the terminals of adrenergic nerves that 
reinforces action on the smooth muscle cells ((89).  
 
Summary 
Overall, the relationship pressure waveform and total blood flow can be explained by fluid 
mechanics. Normal arterial blood flow is laminar with secondary flows generated at curves and 
branches. Arteries are organs that can adopt to change with the varying hemodynamic conditions, 
especially in abnormal biological response. Atherosclerosis for example, can result in localized 
narrowing of the artery lumen, known as stenosis. This can cause turbulence, reduce flow and create 
high shear stresses on the vessel wall. The study of arterial blood flow will lead to the prediction of 
individual abnormal hemodynamic flows and the development of diagnostic tools to quantify vascular 
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diseases such as diabetes. Specific local blood flow mechanisms also exist that are independent of 
extrinsic regulatory control mechanisms such as sympathetic innervation or circulating hormones that 
reinforce a constant flow of blood to an organ. Examples of local control mechanism include 
autoregulation, active hyperemia and reactive hyperemia (89). Retinal circulation is tightly controlled 
autoregulation. Ultimately, the balance between local regulatory mechanisms and extrinsic factors in 
vivo determines the vascular tone and therefore the blood flow within a tissue. 
1.4 Blood Flow Regulation in the Retina 
In the peripheral circulation, blood flow is controlled either by the central nervous system or locally 
by the environmental conditions in the immediate vicinity. Unlike the extra-ocular and choroidal 
vessels that are innervated by the sympathetic and parasympathetic pathways, neural regulation plays 
no known role in the regulation of the inner retinal vasculature (107). Retinal vessels do not have any 
known functioning nerve supply. Since the retina lacks CNS innervations, blood flow is regulated by 
autoregulatory mechanisms via a combination of myogenic driven negative feedback mechanism and 
by metabolic local tissue demands. To ensure adequate oxygen supply, the retina relies heavily for 
matching metabolism on the local vascular control mechanisms termed autoregulation (70).  
1.4.1 Autoregulation in Retinal Blood Flow 
Autoregulation is the ability of a tissue to maintain a constant flow of blood despite variations in 
perfusion pressure (32, 69, 138, 159) and/or metabolic stimuli. The intrinsic ability to autoregulate is vital to 
normal functioning of the retina since retinal vessels do not have a functioning sympathetic nerve 
innervation (4).  Mechanisms of autoregulation have been investigated through experimental isolation 
of tissue from neural and hormonal influences. It has been found that a failure or impairment of 
autoregulation has been implicated in various retinal diseases including diabetic retinopathy (138, 159).  
Guyton and co-workers (1964) expanded the original definition of autoregulation to include tissue 
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responses to changes in blood gas concentrations, often referred to as metabolic autoregulation (70). 
Vascular reactivity is the change in hemodynamic parameters in response to physiological 
provocations including carbon dioxide (CO2) (30, 173, 174, 176), oxygen (O2) (26, 53, 95), cold stress (44, 117, 
120)or light flicker (46, 47, 128). Endothelial dysfunction is an important determinant of altered vascular 
reactivity and plays a major role in the genesis of micro- and macrovascular complications in 
diabetes.  
1.4.1.1 Mechanisms of Autoregulation: Myogenic Mechanism 
The vascular response to acute changes in local blood flow produced by altered perfusion pressure 
occurs via the direct stimulation of smooth muscle stretch receptors within the arteriolar wall (156). 
Dynamic muscular activity was first described in the work of Bayliss (1902), who suggested that 
much like other areas of our body, the smooth muscle layer of arteries respond to a stretching force by 
contraction and to a reduction of tension by relaxation (the Bayliss Effect)(15).  In the retina, an 
increase in transmural pressure has been shown to elicit a myogenic response of isolated retinal 
arterioles (29) . The retinal pre-capillary bed is autoregulated in order to ensure a stable and sufficient 
blood supply despite changes in perfusion pressure (147).  An increase in blood pressure would 
consequently lead to an increase in the blood flow through an arteriole in a non-reactive system. 
However, smooth muscle fibers in the arteriole wall are able to sense this distension and the arteriole 
responds by constricting. This results in an increase in the resistance of the arteriole, thereby 
stabilizing blood flow. The structure of the pre-capillary arterioles with a highly organized smooth 
muscle covering facilitates sensitive control of luminal diameter and effective maintenance of 





1.4.1.1.1 The Loss of Smooth Muscle Cells and Pericytes in Blood Flow Regulation 
The smooth muscle layers are made up of small, mononucleated and spindle shaped cells (10). Similar 
to other smooth muscle in the body, this cell type contracts slowly, develops high force and can 
sustain this force for long periods with low ATP use. The interaction of actin and myosin filaments 
are controlled by myoplasmic Ca++ through voltage gated calcium channels (electromechanical 
coupling) and through receptor-operated calcium channels (pharmacomechanical coupling). In 
diabetic retinopathy, loss of vascular smooth muscle cells (VSMC) is an important factor to the 
downstream capillary bed with a major impact on endothelial cell survival (178).  
 
The ability of these retinal arterioles to regulate flow is important to control blood flow through the 
retinal capillaries. Retinal capillaries lack smooth muscle cells and its endothelium is surrounded by 
pericytes that also exhibit some contractile properties. Studies have shown that the regulation of blood 
flow occurs, not only in the pre-capillary arterioles, but is also fine tuned within the capillary / 
pericyte complex (90, 133, 135). Nevertheless, the role of pericytes in retinal blood flow regulation is 
much less than that of the arterioles. In early exploration of the pathogenesis of diabetic retinopathy, 
one of the earliest abnormalities that predisposes to the formation of microaneurysms are is the loss of 
pericytes (72, 178, 182).   Moreover, Hammes and colleagues found that retinal capillary coverage of 
pericytes is crucial in the survival of endothelial cells, particularly under high stress conditions such 
as the elevated glucose environment of diabetes (72).  Overall, it is clear that the loss vascular smooth 
muscle cells and pericytes contribute to the development of vascular disorders in the retina. 
1.4.1.1.2 Mechanism of Autoregulation: Variations in Systemic Blood Pressure 
Various methods have been applied to test the efficacy of autoregulation to systemic blood pressure 
changes induced by static exercise, posture change and cold pressure test (32, 117, 130). Static and 
isometric exercises notably cause an increase in blood pressure, heart rate and sympathetic nerve 
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activity. Earlier studies that have measured blood velocity changes in the retinal veins following an 
isometric exercise stimulus have found evidence of autoregulation (145).   The effectiveness of 
autoregulation, however, was limited to blood pressure changes of up to 40% from baseline (139). 
Above this point, autoregulation appears to breakdown and velocity increases in a linear manner with 
further increases in blood pressure (33). Intuitively the myogenic mechanism of autoregulation likely 
accounts for the response to perfusion pressure changes caused by an increase in blood pressure.  .  
1.4.1.2 Mechanisms of Autoregulation: Metabolic Autoregulation 
Later in 1967, Guyton and colleagues extended Johnson’s previous notion of retinal 
autoregulation; as the “ability of a tissue to adapt blood flow to metabolic needs” referred to as 
metabolic autoregulation (70). Unlike myogenic autoregulation that stabilizes retinal blood flow, 
metabolic autoregulation changes blood flow to stabilize metabolic requirements. Metabolic blood 
flow regulation alters vascular resistance so that the blood supply maintains the concentrations of 
certain metabolites and waste-products within narrow limits, principally the partial pressure of O2 and 
CO2. We are able to induce a metabolic response and quantify the hemodynamic response, i.e. 
vascular reactivity.  Retinal blood flow is regulated by local factors that modulate vessel 
resistance. These factors are released by the endothelium or by neural tissue surrounding the 
vessel, i.e. neurons, glial and endothelial cells (133, 138). They can be ionic, molecular and/or 
related to arterial gas modification.  
1.4.1.2.1 Metabolic Autoregulation by Ionic/Metabolic Substances 
The release of local ionic/metabolic substances by neurons, glial and endothelial cells can alter 
vascular tone influencing vessel resistance. Endothelial specific derived relaxing factors (EDRF) are 
released by the endothelial cells and elicit a vasodilatory response to increase blood flow (28).  Among 
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the various EDRFs, many studies have shown that nitric oxide (NO) plays a major role in the dilation 
of inner retinal vessels (31, 118, 155). The NO isoform, NOS-3, is expressed in the vascular endothelial 
cells of the retinal vessels, capillaries and pericytes. The existence of a pre-NO gradient from the 
vitro-retinal surface to the vitreous indicates a continuous production of NO to maintain tone. As 
well, oxygen sensitive red blood cells (RBC) can induce an NO-mediated vasodilatory response.  
There are two basic pathways in which NO production leading to a vasodilatory response; flow 
dependent and receptor stimulated NO formation. Flow dependent NO formation is generated by the 
shear stress of blood acting on the vascular endothelium, which causes release of calcium and 
subsequently NO production. In receptor mediated NO formation, endothelial receptors for a variety 
of ligands stimulate calcium release and subsequent NO production. In either situation, vasodilation 
will improve blood flow to tissue with low oxygen affinity. Potent vasodilating factors are subclass of 
prostaglandins; prostacyclin (PGI2). Prostoglandins are produced by the retina and choroid and play a 
role in the physiological regulatory response to hypercapnia and induce dilation (131, 171) and changes 
in ocular perfusion (74). Lastly, adenosine is a product of adenosine triphosphate and a potent 
vasodilator in many vascular beds. Adenosine also plays a role in hypoxia-induced vasodilation and 
retinal autoregulation by potentiating the action of endogenous extracellular adenosine (49, 108). 
 
Endothelial derived constricting factors (EDCFs) elicit a vasoconstricting response.  EDCFs 
include; endothelin-1 (ET-1), angiotensin II, and cyclooxygenase (COX) products, such as 
thromboxane-A2 (TXA2) and prostaglandin H2 (PGH2) (133). Among the various EDCFs, ET-1 is a 
major player responsible for modulation of blood flow in the eye and is expressed by retinal neurons 
and astrocytes. ET-1 has a large influence on retinal arterioles under both normoxic and hyperoxic 




NO and ET-1 are continuously secreted by the surrounding endothelial cells. A fine balance 
between the two opposing factors is critical for proper regulation of the retinal vasculature. A possible 
disturbance of this balance between NO and/or ET-1 has been proposed in diseases such as glaucoma 
(20, 71) and diabetic retinopathy (24, 154). Further, this disturbance has been suggested to trigger a series 
of events that lead to vascular dysfunction found in diabetes (125).  
1.4.1.2.2 Metabolic Autoregulation by Arterial Gases 
Oxygen (O2) is important to retinal function and arterial oxygen tension (pO2) is an important 
determinant of retinal blood flow (56). Arterial oxygen tension is the amount of oxygen dissolved in 
the blood. In healthy individuals, arterial blood entering the capillaries has a pO2 of 100mmHg. The 
inner retinal microcirculation readily adapts to changes in physiological variation in oxygen 
saturation to maintain adequate oxygenation to the neuropile (7).  For this to occur, some mechanism 
must be coupled to determine oxygen utilization within the tissue bed. One possibility is that the 
vascular endothelium serves to control the smooth muscle cell to a variety of circulating vasoactive 
stimuli. Also, within the past decade evidence has suggested that red blood cells themselves respond 
to low O2 environment and respond to the metabolic need of the tissue (34). The demand for adenosine 
triphosphate (ATP) results in an unusually high rate of glycolysis and lactate production. ATP is 
needed for the active neuronal transport processes maintaining the ionic gradients necessary for 
electrical activity and visual transduction (132). As evidenced in human and animal studies, the 
uniqueness of the retinal autoregulation mechanism is its high dependence on arterial oxygen tension, 
unlike for example the cerebral circulation (94).  
 
When oxygenation reaches extreme levels this can have a profound impact on the retina and the 
microcirculation. Exaggerated hyperoxia in certain cases can lead to damaging effect on retinal cells. 
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For example, various oxidants and oxygen free radicals that are associated with ischemic reperfusion 
injury appear to be retinotoxic. Likewise, prolonged oxygen deprivation can also lead to permanent 
damage and trigger retinal pathologies.  A prolonged hypoxic retina by circulatory failure or 
obstruction can stimulate neovascularization by stimulating the production of the growth factor 
VEGF . Recently it has been suggested that vascular tissue stretching increased thymidine uptake and 
VEGF production in capillaries, leading to neovascularization (164, 169).  Chronic hypoxia induces 
endothelial cell proliferation to re-vascularize the deprived retina. The growth of these new, fragile 
and unsupportive vessels can have perilous ramifications on the pre-retinal and vitreous space.   
Improved tissue : oxygenation ratio by laser treatment has been shown to lower VEGF production and 
capillary stretching, reducing new vessel growth through these two mechanisms (3, 8). It is clear that 
oxygen demand must be precise and dynamically balanced through metabolic autoregulation to 
ensure the health of the retina.   Efficient autoregulation of blood flow maintains retinal homeostasis 
over a considerable range of blood oxygen levels as evidenced in the active retina of both 
anaesthetized animal and human models (185).  
 
Analogous to its effect on the cerebral arteries, carbon dioxide also has a potent effect on retinal 
vessel tone.  Hypercapnia (elevated carbon dioxide arterial tension) leads to vasodilation of the retinal 
vessels. Studies that have investigated the normal retinal response to hypercapnia have found 
consistent increases in inner retinal blood flow to CO2 (30, 173, 174, 176, 177) and a relatively exaggerated 
effect on the cerebral vasculature (94). 
1.4.1.2.2.1 Vascular Response to Alterations in Arterial Gas 
The oxygen reactivity of the retinal vascular bed is of major importance to the functional integrity of 
the retina. Moreover, alterations in this tightly regulated system may play a pathogenic role in 
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diabetes mellitus. Impaired vascular reactivity has also been demonstrated in the pathogenesis of 
other retinal diseases, including that of age-related macular degeneration (153, 186), glaucoma (57, 175) and 
diabetic retinopathy(35, 51, 52, 62, 120, 123, 170). Studies that investigate the vessel response to a variation in 
arterial gas may be a useful quantitative evaluation of vascular health.  
 
Decades of studies have described in both animal and human models the hemodynamic response of 
the retina to acute hyperoxia (143), characterized by vasoconstriction and decreased blood velocity. 
Inhaled hyperoxia leads to an increase in arterial partial pressure of O2.  Normal inhalation of 100% 
(hyperoxia) oxygen for 5 minutes cause a 12% and 15% decrease in vessel diameter in the large 
retinal arterials and veins, respectively (62, 143). Hyperoxic induced vasoconstriction reduces blood flow 
of the main retinal artery by up to ~60% and less oxygen penetrates the retina, but the retina receives 
additional oxygen from the less responsive choroidal circulation.  This observation suggests that 
autoregulation occurs mainly in the inner retina; compensating for the variation in oxygen tension by 
adaptation of the inner retinal circulation only.   The underlying mechanism mediating the hyperoxia 
induced vasoconstriction in the retinal bed is still unclear. However, results from animal studies found 
that the vasoconstricting response may be mediated by the increase in ET-1 production (26). 
Biochemical mechanisms mediating vasoconstriction involve the interaction between retinal PO2 and 
L-arginine/nitric oxide (NO) pathways (155).  Patients with diabetes alone and diabetes with 
concomitant hypertension have demonstrated an impairment of vascular response to an isocapnic 
hyperoxia stimulus (50, 51).  
 
Hypoxia, on the other hand, is the decrease in arterial pressure O2. In 1940 Cusick, Benson, and 
Boothby found that inhalation of 10% oxygen (hypoxia) by normal healthy subjects elicits a 
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vasodilatory response of the retinal vessels (105, 163). Relevant mediators responsible for the 
physiological vasodilation of the retinal vessels include prostacyclin and nitric oxide (NO). ET-1 can 
interact with three types of endothelin receptors; ETA, ETB1 and ETB2. Unlike its interaction with ETA 
and ETB1 receptors which leads to vasoconstriction, ETB2- receptor is present on endothelial cells and 
mediates vasodilation via the release of NO (127, 129, 150). Recent studies have found a reduction in ET-1 
levels in patients with NPDR compared to controls, suggesting that this could account for the increase 
in retinal blood flow found in patients with PDR (121). More recent work also strongly suggests that 
retinal arterial vasodilation involves the activation of plasma membrane Ca2+- ATPase (18, 28). Low 
retinal oxygenation has damaging effects on photoreceptors (132) and it is now known to play a role in 
the pathogenesis of various vascular diseases, including diabetic retinopathy, vascular occlusive 
diseases, and glaucoma.  
 
Summary 
Retinal blood flow is regulated by several mechanisms including myogenic and metabolic 
autoregulation.   In order to maintain flow homeostasis and adequate metabolism, these mechanisms 
are unlikely to operate independently of one another.  Blood flow regulation occurs under the 
influence of vasoactive molecules released by endothelial cells. All these autoregulatory mechanisms 
have been shown be disturbed in diabetes mellitus facilitating the breakdown of the blood retinal 
barrier (50, 66, 99, 138, 159). 
1.5 Quantification of Retinal Blood Flow 
The development of imaging modalities has allowed us to characterize the vascular pathology of 
various ocular and systemic diseases, although the outcomes are often contradictory depending upon 
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a number of factors, not least the method of assessment. These modalities and analysis techniques 
facilitate very precise and comprehensive study of retinal, choroidal, and retrobulbar circulations.  
1.5.1 The Doppler Principle 
Discovered in 1842 by Christian Doppler, the Doppler Effect is the change in frequency of a wave 
perceived by a moving observer relative to the frequency of the source of the wave. Laser Doppler 
devices are based on the Doppler principle and are used to assess blood velocity in retinal 
hemodynamics.  Since moving red blood cells are surrounded by stationary tissue, light of non-shifted 
frequency acts as a reference frequency (f). Light reflect by the moving blood cells is Doppler shifted 
and returns with an altered “Doppler shifted” frequency (f’). The velocity of a moving blood cell is 
proportional to the frequency difference (Δf= f – f’) of shifted and non-shifted frequencies. The 
Doppler shift is highly dependent upon the angle (α) between the beam of light transmitted from the 
detector and the moving red blood cells. 
 
 
Figure 1-3  The Doppler principle 
Two frequencies are reflected back from the original beam; 1) light scattered from the 
stationary tissue with frequency f and 2) is the scatter from the red blood cells (moving at 




1.5.2 Laser Doppler Velocimetry 
One approach to measuring retinal blood velocity in retinal arterioles or veins is laser Doppler 
velocimetry (LDV). This approach is based on the principle that the Doppler shift of light is 
proportional to the blood velocity when the vessel is illuminated with a single high coherent laser 
beam. The beam is scattered across the vessel and the moving erythrocytes. The back scatter consists 
of light at the frequency of the light source and the frequency of shifted light. The Doppler shift 
corresponds to a spectrum of all flow velocities. The maximum frequency shift corresponds to the 
maximum centerline velocity within the vessel.  
 
To acquire information of volumetric blood flow, measurement of the vessel diameter is necessary. 
This is accomplished by a fundus camera based technique using photography or continuous video 
recording of the vessel. With the diameter estimation, the cross sectional area of the vessel can be 
found and this is multiplied with the mean flow velocity. The product of blood velocity and vessel 
diameter is an estimation of the volumetric blood flow in a retinal vessel. This approach is currently 
limited, however, to larger vessels and only the maximum center velocity can be determined. 
Quantitative information of the velocity profiles cannot be extracted from the power spectrum. 
Therefore, calculation of flow is based on a theoretical relation between the maximum centerline 
velocity and all other unmeasured velocities within the vessel. The previous optical set-up described 
by Feke and Riva (1978) (41, 142)did not measure absolute velocity due to the difficulty in determining 
the angles between the incident laser light and the moving blood cells. Therefore, the largest problem 
with any Doppler technique that employs a single photodetector is that the measured velocity is 
highly dependent upon the angle between the beam of light transmitted from the detector and the 
moving red blood cells.  
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1.5.3 Bidirectional Laser Velocimetry 
In a complicated system, the reflected Doppler signal contains a large number of velocities. Using 
bidirectional LDV, an absolute determination of maximum centerline blood velocity is possible. To 
quantify the absolute centerline blood velocity, two photo-detectors separated by a known angle are 
used to assess the difference in frequency shift detected between the detectors (41, 141). The two 
photomultiplier tubes are used to sample the Doppler shifted light. Since the magnitude of Doppler 
shift is highly dependent on the angle between the detector and the motion of the erythrocytes and 
angle (α) between the reflective source and two detectors is known, each detector observes a different 
magnitude of Doppler shift. The velocity is determined by the difference in the frequency shift from 
the two directions in which the detectors are orientated, represented as K1 and K2 (Figure 1-4). 
 
 
Figure 1-4 Diagrammatic representation of bidirectional laser Doppler velocimetry. 
The incident beam with frequency (f) strikes to the vessel with red blood cells moving with centre-line 
velocity Vmax. The maximum frequency shift is detected at K1 and K2 that are separated by a known 





When an incident beam strikes the moving red blood cells (RBC) it is known that a vessel that 
exhibits Poiseuille flow will result in a frequency shift of up to a maximum fmax (40). This shift Δfmax 
corresponds to the maximum velocity at the centre of the vessel lumen.   
Δ f max = f2 max – f1 max 
 
Where f1 max and f2 max are the maximum frequency shifts of K1 and K2 are the cut-off 
frequencies recorded from the two directions of scattered light, respectively. First described by 
Riva et al (126), Vmax can be calculated from the difference in f1 and f2 max.  
 
Vmax= k (f2 max – f1 max) 
 
Where Vmax is the maximum centerline velocity of blood and k is a constant dependent on the 
wavelength of the laser, the axial length of the eye, the refractive index of the medium and the 
geometry of the path of the laser light in the fundus camera (126).  
 






where D= vessel diameter and V= mean velocity across a cardiac cycle (40, 184). 
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1.5.4 Canon Laser Blood Flowmeter 
The Canon Laser Blood Flowmeter (CLBF) is the only instrument that applies bidirectional 
quantification of blood velocity while simultaneously measuring vessel diameter to derive retinal 
blood flow in real units. More importantly, since centerline velocity values depend highly on the 
centering of the incident beam on a retinal vessel, the CLBF has a built in eye tracking device that 
eliminates errors caused by significant horizontal saccades. Using this method, reliable results can be 
compared within different areas of one retina or between the retinas of different individuals.  
 
 
Figure 1-5 Photograph of the Canon laser blood flowmeter (model 100). 
Fundus camera like laser head mounted on a table and attached to a chin rest (left). The measurements 
acquired by the CLBF are displayed on a computer (right) and analyzed using custom software 
provided by the manufacturer. 
 
This CLBF displays a 30 degree image of the retina. The instrument is equipped with two 
lasers; a green (543nm, 1500 μm × 150 μm rectangle) HeNe laser used for diameter 
measurements and eye tracking and a red (675 nm, 80 μm × 50 μm ellipse) diode laser used for 
the velocity measurement. The green HeNe laser tracking strip is rotated so that it is 
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perpendicular to the axis of the vessel. The position of the tracking laser on the photodetector 
array is updated every 4 ms and centering is achieved, via a negative feedback loop that controls 
a galvanometer to stabilize the relative position of the green laser, to a precision of ± 5µm under 
normal eye movements (112, 113).  The red ellipse diode laser is centered in the rectangular green 
HeNe laser so that it is also centered onto the target vessel (41). The red laser captures velocity 
measurements every 0.02 sec throughout a 2 sec measuring window. Analysis of the vessel 
image provides a means for vessel diameter measurement. The diameter is determined by 
automatic computer analysis of the signal produced by the image of the vessel; using half the 
(41)height of the transmittance profile to define the vessel column edge. The diameter is measured 
every 4 ms during the first 60ms and during the last 60 ms of each 2sec measurement window. 
Two separate 2 sec measurement windows are required for accurate measurement of a target site 
(path 1 and path 2). The additional measurement with a different incident beam angle eliminates 
ambiguity in the orientation of the incident and scatter beam (38).  
 
Figure 1-6 Photograph of the fundus acquired using the Canon laser blood flowmeter 
Photograph shows fundus including the - optic nerve head, superior temporal arteriole and venule. A 
HeNe laser of 543nm wavelength is centered on the arteriole of interest and oriented perpendicular to 
Venule 
Arteriole 
Red diode laser 
Green HeNe laser 
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the vessel segment for measurement of diameter. The red diode laser is centered within the green laser 
for velocity measurement.  
 
The CLBF is the only device that can calculate volumetric flow in the retina in absolute units and 
has been described in detail elsewhere (40). Older versions of laser technology were unable to 
automatically track the center of a vessel (41, 142). Unlike previous devices that require two separate 
imaging tools (15), the CLBF is the only instrument that simultaneously measures velocity and 
diameter.  
 
The reproducibility of the CLBF has been reported for diameter, average velocity and blood flow in 
separate studies (45, 67, 93, 117, 184). For diameter, coefficient of variation for repeated measurements 
(COV) ranged from 1.9% to 4.9%; for average velocity, COV ranged from 4.7% to 19.9% and for 
blood flow, COV ranged from 6.7% to 19.3%.   
 
Summary 
To date, the CLBF has already proven to be useful in elucidating aspects of physiology and 
pathophysiology in health and disease. In previous investigations of baseline retinal circulation found 
that changes retinal arteriolar pulsatility were related to the risk of developing diabetic macular edema 
(DME) (66). Subsequently, the retinal vascular response to systemic hyperoxia was found to be 
impaired in patients with diabetes and early DR compared to patient with non-diabetes (50).  
Moreover, the investigation of retinal circulatory abnormalities using the CLBF have also been 
investigated in other ocular diseases such as glaucoma (9, 175), age related macular degeneration (153) 
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and blood pressure changes (149) Overall, the CLBF has proven to be an effective tool in the 
investigation of retinal hemodynamics in both health and disease (9, 45, 52, 153, 153) 
1.6 Retinal Hemodynamic Disturbance in Diabetic Retinopathy 
1.6.1 Diabetic Retinopathy 
Diabetic retinopathy (DR) is the leading cause of new vision loss and blindness among working age 
people in the Western world (6). Although the exact mechanism of DR is yet to be elucidated, chronic 
hyperglycemia initiates the process leading to microvascular disruption (59, 63). Two landmark studies, 
the Diabetic Retinopathy Study (DRS) and the Early Treatment Diabetic Retinopathy Study 
(ETDRS), have demonstrated the effectiveness of laser treatment by reducing severe vision loss by 
90%. Further, The Diabetes Control and Complications Trial (DCCT) and the United Kingdom 
Prospective Diabetes Study (UKPDS) established the value of intensive glycemic control in reducing 
the risk of onset and progression of DR and other microvascular abnormalities. 
1.6.2 Clinical Presentation of Diabetic Retinopathy 
Although the pathogenic mechanism of DR has not been clearly defined, the clinical progression of 
DR is well understood. Diabetic retinopathy is classified into two stages; background or 
nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR).  Changes 
in NPDR stage occur in the early phase of the disease and may or may not be followed by PDR, 
which is characterized by neovascularization and vitreous involvement.  
 
Early NPDR results from primarily lesions of the capillary vessels. This later extends to larger 
vessels; venules and arterioles. However, preceding these clinical features of DR, histological 
changes take place that include thickening of the basement membrane, loss of pericytes and smooth 
muscle cells and eventually the formation of microaneurysms. Microvascular changes that are 
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characteristics of NPDR include microaneurysms (MA), blot haemorrhages, cotton wool spots, 
intraretinal microvascular abnormalities (IRMA) and/or macular edema.  
 
Proliferative Diabetic Retinopathy (PDR) is characterized by new vessel growth either on the optic 
disc or on the periphery of the retina. New vessel formation arises when there is a large avascular 
area. This uncontrolled vessel growth develops a fibrous covering which has the potential to break 
through the internal limiting membrane and attach to the posterior surface of the vitreous(96).  
 
Diabetic macular edema (DME) is the most frequent cause of vision loss in patients with diabetic 
retinopathy. The pathogenesis of DME results from the breakdown of the blood-retinal barrier (BRB) 
which leads to the accumulation of fluid within the intraretinal layers of the macula region (12). Local 
factors that influence DME development include angiogenic factors such as vascular endothelial 
growth factor (VEGF), protein kinase C, protaglandins, growth hormones, and the local anatomy of 
the posterior hyaloid face inducing to vitreomacular separation (82). At any direction during the 
progression of DR, patients with diabetes can develop DME.   
 
Overall, several factors are important in the evolution of diabetic retinopathy. One possible 
mechanism in the pathophysiology of DR is abnormal retinal blood flow. Retinal blood flow has been 
investigated and a number of studies have shown vascular dysregulation in patients with diabetes (51, 
58, 66, 98, 122, 159).  
1.6.3 Retinal Hemodynamics in Patients with Diabetes 
Retinal blood flow abnormalities have been investigated in detail in patients with and without 
diabetes. Whether or not, retinal blood flow of patients with diabetes is different from healthy 
 
 35 
individuals is still controversial since there are conflicting evidence between studies. For instance, 
patients with diabetes with no signs of retinopathy have shown to; increase (60), decrease (19, 23) and 
show no difference (39, 50, 65, 66, 122) in changes in blood flow. Studies of patients with background 
retinopathy have also demonstrated an increase (61, 122, 183), decrease (11)and no difference (14, 23, 50, 65, 66) 
in retinal blood flow. Thus, there is evidence that vascular abnormalities occur both before and during 
the development of clinically evident diabetic retinopathy.  
1.6.4 Loss of Compliance in patients with increasing severity of NPDR 
Previously published studies from our lab have found that in homeostatic blood flow measurements, 
there is a loss of compliance, i.e. an increase in rigidity, in early DR including patients with 
increasing risk for diabetic macular edema (DME) development (66). Moreover, arterial stiffness is 
enhanced in patients with diabetes (102) and atheroschlerosis (179). The outcome of arterial stiffness is 
an increase in pulsatile blood pressure from a higher systolic pressure and a lowered diastolic 
pressure. The retinal maximum-to-minimum (max:min) velocity ratio reflects vascular compliance 
where an elevation of max:min ratio indicates increased vascular rigidity (66). The effects of arterial 
rigidity from diabetes, hypertension and age (116) have been found to be detrimental to the retinal 
microvasculature (103, 140, 181).  
1.6.5 Vascular Reactivity in Patients with Diabetes  
Vascular reactivity refers to the response of the blood vessels as a result of a provocation. Non-
invasive and quantitative measurements of retinal blood flow in combination with standardized vaso-
active stimuli have enabled in vivo hemodynamic studies of human retinal vascular bed regulation in 
health and disease. Administration of oxygen (O2) has been used to provoke a response in previous 
studies (50, 51, 53, 54, 62, 64, 95, 123, 143, 163). Overall, retinal blood flow varies inversely with the partial 
pressure of arterial oxygen (PO2) to maintain retinal oxygenation at a relatively constant level. 
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Although healthy human studies have found a reduction in retinal blood flow to 100% oxygen 
breathing, the exact amount is a uncertain; a 60% reduction in retinal blood flow by laser Doppler 
velocimetry (62, 143) whereas others reported a 30% reduction in retinal blood flow (37, 163)by blue field 
entoptic technique. Discrepancies between results can be partly attributed to differences in 
hemodynamic measuring and gas delivery techniques.  
 
Previously published retinal vascular reactivity studies have detailed methods used to deliver the 
hyperoxic stimulus while controlling the arterial partial pressure of carbon dioxide (PCO2) (36, 37, 50, 53, 
148). This is necessary since an increase in PETO2 in hyperoxia tends to result in a concomitant 
reduction in PET CO2. Past studies have used a non-standardized closed loop system while manually 
adding small amounts of CO2 to counteract the PETCO2 change (76, 77, 79). However, this method results 
in high inter-subject variability (22, 146).  Recognizing the need to eliminate the combined effects of 
elevated PO2 and reduced PCO2, a sequential re-breathing system circuit was designed composed of a 
fresh gas reservoir, an expiratory gas reservoir and a face-mask (Hi-Ox
SR
, ViasysHealthcare, 
Yorba Linda, CA). The inspiratory and expiratory limbs are interconnected by a single positive 
end-expiratory pressure (PEEP) valve, allowing exhaled gas to be re-breathed when the gas in the 
inspiratory limb was depleted (54). This system allows for the maintenance of homeostatic PCO2, 
termed isocapnia. This system provides a feedback loop to compensate for any hyperventilation 
induced by a reduction in PCO2.  Therefore, eliminating the exaggerated affects that are caused by 
PCO2. 
 
In the physiological situation, compliance is expected to reduce and rigidity increase during 
hyperoxia due to increased tonus of the vessel wall in response to a vasoconstrictive stimulus. Results 
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from Gilmore et al (50) indicate an inability to increase vessel tonus and reduce shear stress (as 
indicated by the absence of change in max:min velocity ratio and WSR, respectively) with respect to 
an isocapnic hyperoxic provocation in patients with increase risk for DME development. Impaired 
responses to hyperoxia suggest damage in the diabetic vasculature and possibly reflect mechanisms of 
atherosclerosis. This impairment precedes change in homeostatic blood flow parameters. Overall, 
altered vascular reactivity to hyperoxia is a sensitive marker of functional changes in early diabetic 
retinopathy.   
 
Summary 
Retinal arteriolar vasoconstriction caused by an isocapnic hyperoxic stimulus is a useful method to 
test the efficacy of the retina to regulate blood flow. Thus far, studies have indicated that retinal 
vascular dysregulation is an early process in diabetic retinopathy.  
 
1.7 Inflammation and Endothelial Dysfunction in NPDR 
1.7.1 Vascular Inflammation in Diabetes 
Inflammation has been strongly implicated in both diabetes and atherosclerosis (13, 73, 158). Monocytes 
from poorly controlled diabetes patients have shown to induction of inflammatory mediators such as 
protein kinase C and nuclear factor- κβ (27). Particularly, vascular inflammation promotes expression 
of interleukin-6 (IL-6), vascular cellular adhesion molecule-1 (VCAM-1) and monocyte 
chemoattractant protein (MCP-1). Additionally, studies have shown a marked decrease in NO 
bioavailability, leading to impaired endothelial function (80).   Inflammation contributes to the 
pathogenesis of diabetic retinopathy (85, 86, 91, 172), nephropathy (110, 144, 151) and neuropathy (84, 101, 136).  
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1.7.2 Pathogenesis of DR Mechanisms; Retinal Leukostasis  
Although the exact pathogenesis of diabetic retinopathy remains unclear, results from two large 
studies, Diabetes Control and Complications (DCCT) and the United Kingdom Prospective Diabetes 
Study (UKPDS), have confirmed that hyperglycemia is a major factor in the development. Prevailing 
biochemical theories that support the role of glucose in the development of retinopathy include; the 
polyol (sorbitol/aldose reductase) pathway flux, hexosamine pathway (137), accelerated formation of 
advanced glycation end-products (AGEs) (167), hemodynamics changes(97), oxidative stress (104), and 
activation of diacylglycerol and protein kinase C beta (PKCβ) isoforms (180). In 2005, Krady and 
colleagues found that inflammation and the activation of microglia, which are immune cells in the 
central nervous system (CNS) and the retina, play a role in the pathogenesis of DR. Evidence in this 
study suggest an antibiotic with anti-inflammatory properties has the potential to block activation of 
microglia and prevent DR. It is this and other accumulating evidence that suggests that increased 
leukocyte adhesion to the endothelial wall and entrapment (leukostasis) is an early event in DR 
development. NPDR manifests as permeability secondary to inflammatory processes leading to iBRB 
disruption (6), basement membrane (BM) thickening (168), pericytes and smooth muscle loss which 
eventually results in widespread nonperfusion, hypoxia, neovascularization and PDR (91).  
1.7.3 Leukocyte-Endothelial Interaction 
As demonstrated in fluorescein angiography, a sign of diabetic retinopathy (DR) is decreased local 
perfusion, a product of capillary occlusion (100). The exact pathological mechanisms remain unclear. 
Mechanisms that contribute to the degeneration of retinal capillaries in diabetes include 1) occlusion 
of vascular lumen by white blood cells or platelets 2) death of capillaries secondary to biochemical 
abnormalities within the vascular cells themselves 3) death of capillaries secondary to products 
generated by nearby cells (such as neurons or glia) and 4) increased blood viscosity. Recent studies 
have suggested that leukocytes play a key role in DR development. There is now a general acceptance 
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that DR represents a low grade chronic inflammatory disease (2). This inflammatory condition is 
associated with increased leukocyte entrapment (leukostasis) in the retinal capillaries, areas of 
capillary nonperfusion and areas of endothelial damage (87). In the investigation between inflammation 
and retinopathy, the Hoorn study found a close association between inflammatory activity and 
progression of retinopathy (172). Further supporting the involvement of leukocytes, Meleth and 
colleagues (111) also showed a close relationship between serum inflammatory markers, cell adhesion 
molecules, and the severity of diabetic retinopathy.  
 
The pathogenic mechanisms mediating the leukocyte-endothelial cell adhesion include increased 
expression of cell adhesion molecules on the surface of endothelial cells and changes on the leukocyte 
surface. Leukocyte adhesion to the vascular endothelium, a key step to in the inflammatory process, 
involves three steps. The adhesion of leukocytes is largely dependent upon the interactions between 
the endothelial cells and the leukocyte expressed adhesion molecules (55). The initial and key step to 
the recruitment of leukocytes is the “low affinity” attachment to adhesion molecules by three member 
of the selectin family; E-, P- and L- selectin. E-selectin is expressed by the endothelial cells, P-
selectin is expressed by cytosolic storage granules and L-selectins are expressed on leukocyte surface 
(161). The interactions between the selectins and their counter parts cause the “tethered” leukocyte and 
resist detachment caused by physiological shear forces secondary to blood flow. The leukocyte rolls 
along the vascular endothelium drawing it into close proximity facilitating the chemokine-induced 
integrin avidity to the vessel wall (5). The firm adhesion step, resistant to physiologic shear stress, is 









Figure 1-6 A schematic diagram of increased leukocyte-endothelial cell adhesion and 
entrapment (leukostasis) in diabetic retinopathy.   
 Diabetes-induced expression of adhesion molecules, such as intracellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule type 1 (VCAM-1) and E-selectin, causes increased 
leukocyte-endothelial cell adhesion and lead to capillary nonperfusion and vascular damage in diabetic 
retinopathy (adapted from Chibber et al, 2007).  
1.7.4 Circulating Markers of Inflammation 
Early in the inflammatory process, release of chemokines such as monocyte chemoattractant protein 
(MCP-1) and others are released from stressed tissues. In diabetes this has been clearly demonstrated 
in the vascular endothelium and adipose tissue. These chemokines cause an increase in expression of 
interstitial and vascular cell adhesion molecules. Several plasma markers of inflammation have been 
evaluated as potential tools for prediction of microvascular outcomes in diseases such as DR (172). 
Among the markers of systemic inflammation are high sensitivity C-reactive protein (hsCRP) and 
cellular adhesion molecules (CAMs).  Adhesion molecules are endothelial cell surface glycoproteins 
E-selectin 
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that facilitate the attachment of leukocytes in inflammation and include intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin (21, 85, 152).  
1.7.4.1 C-reactive Protein (CRP) 
C-reactive protein (CRP) is a prototypic marker of underlying systemic inflammation. CRP is 
synthesized by the liver and responds to factors released by the adipose cells. These factors increase 
the expression of vascular cell adhesion molecules and attract monocytes that gain access to stressed 
sites. At the site of inflammation, chemokine induced proliferation and pro-inflammatory gene 
activation produces cytokines, like members of the interleukin (IL-) family. Interleukin-6 (IL-6) 
appears to be an important stimulator of CRP production. Therefore, CRP is a clinically relevant 
marker of inflammation.   These underlying factors stimulate endothelial induced expression of genes 
that include: reactive oxygen species (ROS), oxidized lipids, reduced nitric oxide (NO), increase 
angiotensin II and advanced glycation end products (AGE). The combination of endothelial derived 
factors and macrophage migration contribute to the generation of altered vaso-reactivity through the 
establishment of a procoagulant state via expression of a series of platelet activating factors such as 
factor VIII. Many of these enter the blood circulation at levels that have been found to correlate with 
the degree of inflammatory activity. Studies have demonstrated the association between CRP and the 
incidence of diabetes development (172)  
1.7.4.2 Intercellular Adhesion Molecule-1 (ICAM-1) 
Intercellular adhesion molecule type 1 (ICAM-1), also known as CD54, is a ubiquitous trans-
membrane glycoprotein that is a key mediator in leukocyte migration and activation. ICAM-1 
functions as a ligand for LFA-1 (CD11a/CD18) which is leukocyte expressed. At the site of 
inflammation, ICAM-1 is up-regulated and mediates adhesion of leukocytes expressing LFA-1. This 
protein is basally expressed on a limited number of endothelial cells and monocytes. It is widely 
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inducible or up-regulated by endothelial cells, lymphocyte and macrophage (160). Estimate of the mean 
level sICAM-1 range from 102-450 ng/ml in normal individuals (48). sICAM-1 has been reported in 
inflammation, allergy, autoimmune diseases, infections and cancers. Specifically, elevated levels of 
sICAM-1 are associated with cardiovascular disease, type 2 diabetes, hypertension, organ transplant 
dysfunction, oxidant stress, liver disease and certain malignancies (160).  Investigative animal studies 
found that mice deficient in CD18 and ICAM-1 had reduced adherent leukocyte, less endothelial cell 
damage and lesser vascular leakage, which are key in the early development of diabetic retinopathy 
(85).  Studies have found that the prevalence of DR is positively associated with measured levels of 
soluble ICAM-1 (172).  This highlights the important role of ICAM-1 in retinal leukostasis and in the 
pathogenesis of DR. 
1.7.4.3 Vascular Cell Adhesion Molecule-1 (VCAM-1) 
Vascular cell adhesion molecule type 1 is also a glycoprotein belonging to the immunoglobulin super 
family. The counterpart for VCAM-1 is the VLA-4, an integrin expressed on the family of 
leukocytes: monocytes, lymphocytes, basophils and eosinophils. VCAM-1 is expressed on cytokine 
activated endothelial cells, dendritic cells, macrophages and epithelium. Unlike ICAM-1, VCAM-1 is 
not significantly expressed on un-stimulated endothelial cells.  Estimates of the mean level of 
sVCAM-1 range from 431-504 ng/ml in normal individuals (48). Increased sVCAM-1 has been found 
to be associated with inflammation, infectious diseases, vasculitus and diabetes mellitus (160). 
1.7.4.4 E-selectin 
E-selectin is considered a specific marker of activated endothelium exclusively expressed by 
endothelial cells. Unlike ICAM-1 and VCAM-1 which are expressed by different types of cells, the 
origin of circulating E-selectin is easily identified. The restriction of E-selectin expression to 
activated endothelium makes this adhesion receptor an ideal marker of endothelial cell activation. The 
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normal levels of E-selectin range from 1-50 ng/ml (160). Marked elevation of E-selectin occurs in 
plasma of patients with septic shock, a condition of acutely decreased tissue perfusion and oxygen 
delivery, an example in which this marker serves as a sensitive parameter for widespread endothelial 
cell injury. Specifically, E-selectin has been found to be elevated in patients with hypertension. The 
absence of correlation between E-selectin and von Willebrand factor, a marker of endothelial injury, 
suggests that elevated levels of E-selectin in hypertension do not reflect endothelial injury but rather 
an altered endothelial cell activity. Previous studies found that baseline sE-selectin levels were 
associated with progression of retinopathy (162). 
 
Soluble forms of these both adhesion molecules ICAM-1, VCAM-1 and E-selectin have been 
described and detected in the plasma and other bodily fluids. In the investigation between 
inflammation and retinopathy, the Hoorn study measured levels of C-reactive protein (CRP), soluble 
intercellular adhesion molecule (sICAM-1), von Willebrand factor and soluble vascular cell adhesion 
molecule (sVCAM-1) (172).  The increased levels of circulating adhesion molecules, thus, may reflect 
local expression of adhesion molecules in an immuno-pathologic process. Studies of immuno-
pathologic diseases have identified different patterns of expression which are dependent on the 
disease stimulus. Although many results that support diabetes induced changes come from large 
vessels, studies do suggest that high glucose promotes upregulation of cell surface adhesion 
molecules such as ICAM-1, E-selectin, P-selectin (88) in both human and animal models. In vitro 
studies in cultured human retinal capillary endothelial cells (HREC), confirmed that high glucose 
enhances leukocyte-endothelial interaction through increased ICAM-1 expression (83).  Similarly in 
human studies, soluble forms of ICAM-1 and VCAM-1 were found to be up-regulated and correlated 
with DR severity (92, 119). The close association between high expression of adhesion molecules and 
the severity of DR suggests an important role in the development DR. 
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1.7.5 Endothelial Cell Dysfunction in Type 2 Diabetes 
Endothelial dysfunction is defined as changes to the endothelial properties, as a result of injury, that 
can lead to its abnormal function. In terms of blood serum markers, this can be clinically assessed by 
von Willebrand factor production; a marker of endothelial cell injury.   Amongst the widely 
distributed circulating adhesion molecules that potentially reflect inflammation, von Willebrand 
factor (vWF) released specifically by the endothelial cells reflects vascular endothelial injury and 
dysfunction. This marker has been shown to be important in diabetic retinopathy development. 
1.7.5.1 von Willebrand Factor  
Endothelial cells normally present a non-thrombogenic and anticoagulant surface for the flow of 
blood. However, following vessel damage and damage to the endothelial cells, their properties are 
modulated to ensure effective platelet aggregation and haemostatic plug formation. One of the main 
endothelial mediators for platelet formation is von Willebrand factor (vWF). vWF is a multi-dimeric 
glycoprotein that is secreted by exocytosis from granular stores (124). It assists factor VIII in the 
formation of fibrin at the site of injury. Since vWF release is increased when endothelial cells are 
damaged, vWF levels have been a proposed indicator for endothelial dysfunction.   Abnormalities of 
vWF have been demonstrated with patients with diabetes and may be involved in diabetic 
vasculopathy (165). In diabetic retinopathy, Feng and colleagues found that increased vWF was 
associated with prolonged retinal circulation time and reduced retinal blood flow in patients with 
minimal or no DR (42). However, the results of other studies with respect to vWf as a predictor of 
abnormal endothelial secretory function were less convincing (109).  Despite the discrepancies in the 







In recent years, increasing evidence suggests DR is a low-grade chronic inflammatory condition 
associated with leukocyte adhesion to the diabetic vasculature. Abnormal leukocyte-endothelial 
interactions are the result of increased expression of surface adhesion molecules (ICAM-1 and 
VCAM-1) that attach to specific integrin counterparts, leading to leukostasis. Moreover, endothelial 
dysfunction has been found to be marked by high expressions of endothelial specific proteins E-
selectin and vWF in patients with DR.  With the accumulation of leukocytes and endothelial cell 
changes, this is thought to lead to an increase in vessel permeability, ultimately influencing retinal 
blood flow. Overall, leukostasis and endothelial dysfunction has been found to be involved in the 





















Many of the clinical changes in DR are thought to be related to abnormalities in retinal blood flow (9, 
16, 23, 24), although direct proof of such a relationship is lacking. Work from our laboratory indicates 
that disturbance of retinal hemodynamics may provide a useful surrogate marker of the clinical 
progression of diabetic retinopathy (10). Guan and co-workers (2006) found an increase of velocity 
pulse wave amplitude with increasing severity of mild-to-moderate NPDR indicating a loss of vessel 
compliance in early DR and the development of DME. The same study found no difference in 
arteriolar diameter, velocity and blood flow in the identical cohort. 
 
There is also increasing evidence for the loss of retinal vascular regulation / reactivity in the 
diabetic vasculature (17, 24). The retinal vasculature regulates local blood flow using intrinsic 
mechanisms, rather than being under central nervous system control. The blue field entoptic 
technique (24), flicker stimulus(6) and gas provocation (5) are a few methods applied to evaluate 
vascular regulation in patients with diabetes. Earlier studies found that the retinal vascular reactivity 
response to a non-standardized 100% oxygen breathing was reduced in diabetic patients with a wide 
range of DR including PDR. Our laboratory has recently developed an isocapnic hyperoxic stimulus 
to evaluate the vascular reactivity of retinal arterioles and found an impaired response in patients with 
early DR and increasing potential for development of diabetic macular edema (7). The response of 
smooth muscle cells and endothelial cells to local metabolic factors is thought to be altered in 
diabetes, disrupting retinal vascular regulation.  The standardized isocapnic hyperoxic provocation 
has proven to be an effective and reliable method to assess the magnitude of retinal vascular reactivity 




Abnormal leukocyte adhesion (i.e. leukostasis) to retinal vascular endothelial cells also occurs 
relatively early in diabetes (19). Vascular damage is shown to be temporally and spatially associated 
with retinal leukostasis in experimental diabetes (12). In non-proliferative DR, clinical outcomes are 
manifested by endothelial cell damage (1, 25), excessive permeability due to BRB disruption and 
subsequent dropout of retinal capillaries resulting in nonperfusion (2). Hyperglycemia is suggested to 
promote vascular damage in DR by signaling the release of inflammatory cytokines which triggers 
the upregulation of vascular adhesion molecules (20). Tumor necrosis factor alpha (TNF-α) is a 
proinflammatory cytokine that can stimulate vascular endothelial growth factor (VEGF) expression 
by the retinal pigment epithelium. Besides its angiogenic properties, VEGF up regulates intercellular 
adhesion molecule type 1 (ICAM-1) expression resulting in leukostasis and increased vascular 
permeability (4, 4, 11). Other adhesion molecules such as soluble vascular cell adhesion molecule type 1 
(VCAM-1) and E-selectin have also been known to participate in the attachment of leukocytes in the 
diabetic retinal vasculature (3, 15, 21).   
 
Earlier studies have shown abnormalities of blood flow parameters along with increased leukocyte 
adhesion in the retinal capillaries in animal models, suggesting that these changes may represent a 
precursor to any clinical findings (18, 19). Further, the Hoorn study has shown that circulating markers 
of inflammation and endothelial dysfunction are positively associated with clinical signs of DR (25). 
However, the temporal relationship between abnormal retinal hemodynamics and increasing 
inflammatory activity or increasing endothelial dysfunction markers in NPDR in humans is unknown.  
Since blood flow into the capillary bed is largely determined by the upstream arterioles, it is essential 
to determine the relationship between leukostasis and retinal hemodynamics since one change may be 
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predictive of the other, thereby providing the possibility to develop surrogate markers.  Excessive 
perfusion pressure may lead to capillary leakage effectively via hyperfiltration (Starling’s Law), 
protein leakage, edema formation and damage to the capillaries and surrounding tissue. We 
hypothesized that an increase in circulating soluble adhesion molecules, signaling increased 
inflammatory activity, and an increase in endothelial dysfunction markers are associated with retinal 
hemodynamic disturbance in patients with early diabetes. The potential changes in retinal blood flow 
may be secondary to increased expression of cytokines or vice versa.  This study would potentially 
lead to a further understanding of DR on a biochemical / cytokine-functional level and will ultimately 
lead to earlier and more effective therapeutic intervention. Overall, the results of such study may have 
important health implications.  
 
The global purpose of this work is to assess the relationship between levels of circulating markers 
of inflammation and endothelial dysfunction and retinal hemodynamic parameters in patients with 
increasing severity of early NPDR.  In patients with diabetic retinopathy, the following candidate 
molecules have been found to be elevated; intracellular adhesion molecule-1 (ICAM-1) (13), vascular 
adhesion molecule-1 (VCAM-1), E-selectin (14) and high sensitivity C-reactive protein (hs CRP) (8). A 
marker of endothelial dysfunction in DR is von Willebrand factor antigen (vWf ag) (22).  Using 
standardized techniques developed in by our group, retinal blood flow and vascular reactivity to 
isocapnic hyperoxic provocation will be assessed. The association of inflammatory activity, 
endothelial dysfunction and arteriolar retinal hemodynamics will be investigated.  
2.1 Aims  
The first aim of the study is to determine the associations between markers of inflammation, 
endothelial dysfunction and retinal hemodynamic disturbance in type 2 diabetes; retinal 
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hemodynamic disturbance will be assessed in terms of baseline values and change over a 6-month 
period (Chapter 3). Inflammatory and endothelial dysfunctional makers (sICAM-1, sVCAM-1, 
sE-selectin, hs CRP and vWF) will be quantified and compared at baseline and then correlated 
with retinal hemodynamic parameters at baseline and in terms of change in hemodynamics over a 
6-month period. Retinal hemodynamic parameters in this study include retinal arteriolar vessel 
diameter, centerline blood velocity, maximum-to-minimum velocity ratio and volumetric blood 
flow. We hypothesize that: 1) baseline arteriolar hemodynamics and 2) the magnitude of retinal 
hemodynamic disturbance over 6-month time are positively correlated with systemic markers of 
inflammation and endothelial dysfunction in type 2 diabetes.  
 
The second aim of the study is to determine the associations between markers of inflammation, 
endothelial dysfunction and the magnitude of retinal vascular reactivity in type 2 diabetes; retinal 
vascular reactivity will be assessed in terms of the response of the vessels to isocapnic hyperoxic 
provocation at baseline and in terms of change over a 6-month period (Chapter 4). Inflammatory and 
endothelial dysfunctional makers (sICAM-1, sVCAM-1, sE-selectin, hs CRP and vWF) will be 
quantified and correlated with retinal hemodynamic parameters at baseline and in terms of 
change in hemodynamics over a 6-month period. Hemodynamic parameters in this study include 
retinal arteriolar vascular reactivity to an isocapnic hyperoxic provocation in terms of the 
measured response in vessel diameter, centerline blood velocity, maximum-to-minimum velocity 
ratio and volumetric blood flow. We hypothesize that; 1) the magnitude of retinal vascular 
reactivity at baseline 2) the disturbance of retinal vascular reactivity over 6 month time and are 
positively correlated with systemic markers of vascular inflammation and endothelial dysfunction 




Overall, the results of this study may have important health implications. This study aims to associate 
molecular (circulating markers of inflammation and endothelial dysfunction) and functional 
biomarkers (vascular function, retinal hemodynamics and arterial stiffness) that are thought to be 
relevant to the pathogenesis of early DR. If a relationship exists between circulating markers of 
inflammation and/or endothelial dysfunction and retinal hemodynamics then perhaps one or the other 
of these assays depending upon application, can be used as surrogate markers of vascular health.  The 
discovery of such a relationship would significantly improve our understanding of the pathogenesis of 
early DR. Moreover, this study could indicate that standardized imaging techniques may provide 
tangible ways of predicating risk or monitoring progression of DR in patients.  This study would 
potentially lead to a further understanding of DR on a molecular / cytokine-functional level and could 














Baseline Retinal Hemodynamics, Systemic Markers of Vascular 
Inflammation and Endothelial Dysfunction in Type 2 Diabetes 
3.1 Overview 
Purpose: The purpose of this study was to investigate in patients with type 2 diabetes and non-
proliferative
 
 DR (NPDR): 1) The concomitant disturbance of retinal blood flow and systemic markers 
of vascular inflammation and endothelial dysfunction and 2) the associations between retinal blood 
flow and systemic markers of vascular inflammation and endothelial dysfunction. 
Methods: This study consisted of 12 Group 1 control subjects, 25 Group 2 patients with mild-to-
moderate NPDR (mean age 54 ± 11 y.o) and 13 Group 3 patients with moderate-to-severe NPDR 
(mean age 60 ± 11 y.o). At the first visit, baseline retinal arteriolar diameter, blood velocity, 
maximum-to-minimum velocity ratio and flow were assessed non-invasively using the Canon Laser 
Blood Flowmeter (CLBF). From forearm blood, plasma concentrations of vascular inflammatory 
markers (sICAM-1, sVCAM-1 and sE-selectin) and the endothelial dysfunction marker (vWF 
antigen) were assessed by enzyme-linked immuno-sorbent assay methods. Hs CRP and A1c were also 
assessed at this visit. After 6 months, retinal hemodynamics was re-evaluated. The baseline systemic 
markers of vascular inflammation and endothelial dysfunction were correlated with baseline and 
change (Δ) in retinal hemodynamic parameters over a 6 month follow-up period and compared 




Results: Maximum-to-minimum velocity ratio was found to be significantly elevated in the group 3 
compared to group 1 at baseline (0.72 vs. 0.49, ANOVA p<0.01) and at the follow-up visit (0.77 vs. 
0.55, t-test p=0.02). However, there were no significant differences in vessel diameter, blood velocity 
and flow between groups at baseline (visit 1) or follow-up visit (visit 2). There were no significant 
differences found within or between Group 2 and Group 3 in terms Δ in retinal hemodynamic 
parameters over the follow-up period.  
 
Both sICAM-1 and sE-selectin were significantly elevated as a function of group (ANOVA p=0.02 
and p=0.04).  A post hoc Bonferroni test showed that Group 3 had significantly higher sICAM-1 and 
sE-selectin levels compared to Group 1 (234.0 vs. 151.5 ng/ml, P=0.02 and 53.4 vs. 27.6 ng/ml, 
P<0.01, respectively). VCAM-1 and vWF were not statistically different (ANOVA p=0.25 & p=0.69, 
respectively) between groups. Hemoglobin A1c was significantly elevated across the groups 
(ANOVA p<0.01), with Group 3 having significantly higher hemoglobin A1c levels compared to 
Group 1 (7.9 vs. 5.6 %, P<0.01).  
 
There were no significant associations found between baseline markers of inflammation and baseline 
retinal hemodynamics across all groups.  
 
Δ velocity was correlated with the baseline sICAM-1 (r=0.42, p=0.02) and A1c levels (r=0.37, 
p=0.04) in patients with NPDR. After adjustment for all other variables (A1c, hsCRP and vWF), Δ 





Conclusion: Overall, we found both an increase rigidity of the arteriolar circulation at baseline and 
follow-up and an increase vascular adhesion markers sICAM-1 and sE-selectin within the same 
population sample. Change in velocity over the follow-up period was correlated with sICAM-1 and 
A1c levels in patients with NPDR but the level of association was such that neither sICAM-1 and A1c 
proved to reliably predict retinal hemodynamics. 
 
3.2 Introduction 
Many of the pathological changes in non-proliferative diabetic retinopathy (NPDR) are thought to be 
related to abnormalities in retinal blood flow (11, 25, 42, 43, 62), although proof of a cause and effect 
relationship is still lacking. Previously reported retinal blood flow results in patients with NPDR are 
conflicting (61). A variety of techniques have been utilized for the measurement of blood velocity and 
flow and this may contribute to the heterogeneity of the results. However, a disturbance in retinal 
vessel pulsatility has been an accepted marker of change in early diabetic retinopathy (DR) (27).   
Using laser Doppler velocimetry and simultaneous vessel densitometry, our group has shown an 
increase of retinal arteriolar velocity pulse wave amplitude with increasing severity of mild-to-
moderate NPDR in type 2 diabetes, indicating a loss of vessel compliance in relatively early DR that 
includes the development of DME (27). There is also increasing evidence for a loss of retinal vascular 
regulation / reactivity to isocapnic hyperoxia in the vasculature of patients with early DR (44, 62). A 
number of papers have been published using the quantitative laser Doppler velocimetry and 
simultaneous vessel densitometry technique to quantify the magnitude of volumetric blood flow 
perturbation as result of some form of provocation and due to the patho-physiological influence of 




Leukocyte-endothelial interaction plays an important role in the early development of DR (32, 48, 
50, 55, 66). A component of DR is a low-grade chronic vascular inflammation associated with 
increased leukocyte entrapment in the retinal vasculature (5). The inflammatory process, termed 
leukostasis, is secondary to the enhanced expression of soluble adhesion molecules (5, 32, 56, 66). 
These inflammatory mediators include soluble intercellular adhesion molecule (sICAM-1)(45, 
47)(37, 54, 66), vascular cell adhesion molecule (sVCAM-1) (37, 54, 66) and sE-selectin (41). In turn, 
endothelial cell injury results in the expression of endothelial dysfunction marker von Willebrand 
factor antigen (vWF), the up-regulation of which has also been found to be related to the severity 
of DR (6, 16).  
 
The purpose of this study was to investigate in patients with type 2 diabetes and non-
proliferative DR (NPDR): 1) The concomitant disturbance of retinal blood flow and systemic 
markers of vascular inflammation and endothelial dysfunction and 2) the associations between 
retinal blood flow and systemic markers of vascular inflammation and endothelial dysfunction. 
Earlier studies have shown that specific circulating markers of vascular inflammation and 
endothelial dysfunction are associated with clinical signs of DR (66). However, it is not known if 
markers of vascular inflammatory activity or endothelial dysfunction relate to retinal arteriolar 
hemodynamics in patients with early NPDR. If a relationship exists between circulating markers 
of inflammation and/or endothelial dysfunction and retinal hemodynamics in early NPDR then 
perhaps quantitative measurement of retinal hemodynamics can be a surrogate marker of vascular 
health and ultimately it can be used as a monitoring tool for patients with diabetes. Moreover, 
this study will lead to a further understanding of early DR through the definition of the 
relationship between a biochemical markers and functional measurements of vascular health.  
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3.3 Materials and Methods 
3.3.1 Sample 
The sample comprised 12 non-diabetes control subjects (Group 1, 6M: 6F, mean age of 54 ± 11.6 
yrs), 25 mild-to-moderate NPDR patients with type 2 diabetes (Group 2, 13M: 12F, mean age of 64 ± 
8.3 yrs) and 13 moderate-to-severe NPDR patients with type 2 diabetes (Group 3, 6M: 7F, mean age 
of 60 ± 11.1 yrs) (see Table 3-1). All volunteers were between the ages of 35 and 75 years and had a 
logarithm of the minimum angle of resolution (log MAR) visual acuity of 0.30, or better. Subjects 
were excluded from the study if they had a refractive error greater than ±6.00 DS and/or ±2.5 DC, 
ocular disease or disorder (other than evidence of DR), and a history of ocular surgery. Participants 
with nuclear opalescence, nuclear colour and posterior subcapsular cataract greater than 3, and 
cortical cataract greater than 2, as defined by the Lens Opacity Classification System III were also 
excluded (10). Subjects taking medications with known affects on blood flow (except for well 
controlled systemic hypertension) or have known rheumatologic diseases were excluded from the 
study. To eliminate the confounding effect of vasoactive medications that could affect blood flow 
(e.g. beta-blockers), all hypertensive medications were kept constant throughout the study. 
Control subjects were excluded from the study if there was an existing, or history of, diabetes and/or 
glaucoma in a first degree relative. The glaucoma exclusion criterion was also applied to the diabetic 
patient groups.  
 
This study was approved by the University of Waterloo Office Of Research Ethics, Waterloo, 
and by the University Health Network Research Ethics Board, Toronto. Informed consent was 
obtained from each participant after a thorough explanation of the nature of the study and its 
possible consequences, according to the tenets of the Declaration of Helsinki. 
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Group n Group 





# of patients 
using 
insulin  






1 12 54 
(11.6) 
n/a n/a 6:6 5.6 
(0.4) 




5 13:12 7.0 
(1.7) 




2 6:7 7.9 
(2.0) 
Table 3-1: Demographic details of the study sample. 
Sample size per group (n), group mean age (standard deviation, SD), reported duration of diabetes 
(years), number (#) using insulin treatment, male: female, and glycosylated hemoglobin (A1c) as a 
function of group.  
 
3.3.2 Methodology 
Each volunteer underwent assessment to establish the overall DR status and a general health profile 
screening to determine study eligibility. This assessment included contact lens stereo fundus 
biomicroscopy, binocular indirect ophthalmoscopy and digital stereo fundus photography (Canon CR-
DGi with a 12.8 megapixel DSLR back; Canon, Tokyo Japan). One eye of each eligible patient was 
randomly assigned to the study. Prior to dilation with 1% tropicamide (Alcon Canada Inc), refraction, 
logarithm of the minimum angle of resolution (log MAR) visual acuity, intraocular pressure (IOP) 
and resting blood pressure were assessed. All subjects were given a topical anesthesia (Alcaine; 
Alcon, Mississauga, Canada), prior to undertaking Goldmann applanation tonometry to IOP. 
Following pupil dilation and fundus photography, assessment of the presence and severity of lens 
opacity was undertaken. Volunteers were allocated into groups according to their retinal status 
defined using dilated stereo fundus biomicroscopy 1991}. Participants were categorized into two 
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groups based on their risk factors for progression of proliferative diabetic retinopathy: mild-to-
moderate (Group 2) or moderate-to-severe NPDR (Group 3).  
3.3.2.1 Quantitative Assessment of Retinal Arteriolar Vessel Diameter, Centerline Velocity 
and Blood Flow  
Non-invasive retinal arteriolar blood flow was quantified using the laser Doppler velocimetry and 
simultaneous vessel densitometry technique as incorporated into the Canon Laser Blood Flowmeter 
model 100 (CLBF: Canon, Tokyo, Japan). The technique and instrument has been described in detail 
in Chapter 1. Briefly, this instrument is comprised of a fundus camera with two lasers and a pair of 
photo-detectors incorporated into the unit. The principal underlying the CLBF is based on the 
Doppler effect. A red diode laser (675 nm, 80 x 50 µm oval) is used to measure velocity and a second 
green diode laser (543nm, 1,500x150µm rectangle) tracks eye movement stability and measures 
vessel diameter.  A vessel that obeys Poiseuille’s flow produces a range of velocities up to a 
maximum frequency shift (15, 58). The maximum shifted frequency, Δf max, are the red blood cells 
(RBCs) flowing through the center of the retinal vessel and corresponds to the maximum velocity (V 
max) of moving particles. The combination of the average velocity (Vmax) over a pulse cycle and 
diameter (D), we can calculate flow. 
Flow= ½ x (П/4) x Vmax x 60 x D2. 
In summary, absolute measurements of vessel diameter (µm), velocity (mm/s) and flow (µl/min) are 
obtained (For technical summary see Kida et al., 2002 (38); Canon, 1997). The method has been 





At visit 1, volunteers underwent eligibility screening, group assignment, baseline homeostatic retinal 
blood flow measurements and blood work. At this visit, at least six retinal hemodynamic readings 
were taken of the supero-temporal arteriole. Each acquired measurement assessed the arteriolar 
diameter, blood velocity, max:min velocity ratio and blood flow. The site of CLBF measurement was 
approximately 1 disc diameter from the edge of the optic nerve head along a relatively straight 
segment of the supero-temporal arteriole and distant from any bifurcations. Forearm blood samples 
were collected for the quantification of plasma sICAM-1, sVCAM-1, sE-selectin, vWF Ag, A1c and 
hs CRP levels.  Further, blood pressure was also measured at this visit. At visit 2, at least 6 additional 
retinal hemodynamic measurements were taken using the CLBF at the identical arteriolar site as in 
visit 1. “Δ” was defined as the difference between each retinal hemodynamic parameter at visit 1 and 
visit 2 in terms of arteriolar diameter, blood velocity, max: min velocity ratio and blood flow.   
3.3.3.1 Molecular Markers of Vascular Inflammation and Endothelial Dysfunction  
Forearm blood sample was collected prior to retinal hemodynamic assessment for each patient. For 
vascular inflammatory markers sICAM-1, sVCAM-1 and sE-selectin, blood was collected into a 7 ml 
heparin vacutainer and plasma was obtained by centrifugation. The plasma sample was then separated 
into polystyrene tubes in 4 equal amounts (one sample tube for each marker plus an additional sample 
if a test was to be repeated) and stored at -80oC until assayed. Plasma samples were determined using 
standard, validated techniques via enzyme-linked immunosorbent assay methods (R&D Systems, 
Minneapolis, MN). The assay is the standard ELISA sandwich enzyme immunoassay technique and 
was performed by an experienced lab technician (see Appendix A).  
 
Blood samples were also collected at baseline from all patients with diabetes and controls for the 
quantitative determination of von Willebrand factor antigen (vWF Ag), a marker of endothelial 
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dysfunction, in plasma and assessed with an immuno-turbidimetric assay (STA-Liatest vWF, 
Diagnostica Stago, France) (see Appendix A).  
 
In terms of the manufacturers reported reproducibility, the coefficient of variation (COV) of 
sICAM-1, sVCAM-1 and sE-selectin was found to be 2.3-6.6% for intra-assay precision (tested 
twenty times) and COV of 4.4-7.8% for inter-assay precision (tested forty times) (R&D Systems, 
Minneapolis, MN). 
3.3.3.2 Additional measurements of diabetes related complications 
Additionally, blood pressure, hemoglobin A1c and hs CRP were also measured.  Hemoglobin A1c 
was quantified using ion exchange high performance liquid chromatography (HPLC) (Bio-Rad 
Variant, Bio-Rad Laboratories, Montreal, Canada), While high sensitivity C-reactive protein was 
quantified by Immuno Nephelometry (NII nephelometer, Siemens Healthcare Diagnostics (previously 
Dade Behring), Deerfield, Illinois). The assay was completed by a trained lab technician.  
3.4 Analysis 
3.4.1 Blood Flow Analysis 
Axial length and refractive error data of each study eye was used to correct CLBF measurements for 
magnification effects. A post-acquisition analysis of the velocity waveforms were performed using a 
standardized laboratory protocol to remove aberrant waveforms affected by eye movements, tear film 
breakup, or improper tracking of the measurement laser. Velocity waveforms were accepted if there 
was a minimum of one complete cardiac cycle which was not adversely affected by major eye 




The data was analyzed using Statistica 9.0 software for windows (Statsoft Inc, Tulsa, OK-USA). 
The normality of data of each hemodynamic parameter and systemic blood markers were checked 
prior to the use of parametric statistics. The maximum-to-minimum velocity ratio was log 
transformed to satisfy statistical normality. Differences between groups for each inflammatory 
(sICAM-1, sVCAM-1, and E-selectin), endothelial dysfunction markers (vWF), A1c and hs CRP 
were analyzed using One-way ANOVA. Similarly, differences in retinal hemodynamic parameters 
(blood vessel diameter, blood velocity, and blood flow) between groups were also analyzed using 
One-way ANOVA. For all significant One-way ANOVAs, Bonferroni post hoc tests were used in 
order to reduce Type I experimental errors. “Δ” was defined as the difference between each 
retinal hemodynamic parameter at visit 1 and visit 2 in terms of arteriolar diameter, blood velocity, 
max: min velocity ratio and blood flow.  Change (Δ) in each hemodynamic parameter between 
Groups 2 and 3 were tested using paired t-tests.  Significant correlations between markers of 
inflammation, endothelial dysfunction, A1c, hs CRP and retinal hemodynamic parameters at baseline 
and Δ were analyzed using bivariate Pearson correlation. All significant associations are entered 
into a multiple regression model to assess whether the dependent variable (a given hemodynamic 
parameter) could be predicted from markers of vascular inflammation and endothelial dysfunction 
(independent variables).  
3.5 Results 
3.5.1 Baseline, follow-up and change (Δ) over 6 months time in retinal hemodynamic 
parameters 
Baseline (visit 1). Group mean values for the retinal hemodynamic parameters vessel diameter, blood 
velocity, flow and log max:min velocity ratio at baseline are found in Table 3-2 and are illustrated in 
Figure 3-1.  Maximum-to-minimum velocity ratio was found to be significantly elevated in the group 
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3 compared to group 1 at baseline (0.72 vs. 0.49, ANOVA p<0.01) and at the follow-up visit (0.77 vs. 
0.55, t-test p=0.02). However, there were no significant differences in vessel diameter, blood velocity 
and flow between groups at baseline (visit 1) or follow-up visit (visit 2).  
Baseline Retinal 
Hemodynamics 









































Table 3-2: Group mean retinal hemodynamic parameters at baseline visit. 
Vessel diameter, blood velocity, log maximum-to-minimum ratio and blood flow (standard deviation) 
as a function of group. A p< 0.05 is considered statistically significant. (* indicates significantly 






Figure 3-1: Baseline retinal hemodynamic parameters as a function of group.  
Vessel diameter (upper left), blood velocity (upper right), blood flow (bottom left) and log maximum-
to-minimum velocity ratio as a function of group. For each graph, the center of the box represents the 
group mean level, the limits of the box represent ±1 SE and the whiskers represent ±1 SD. An open 
circle represents outlier values. Group 1; age matched controls, Group 2; mild-to-moderate NPDR, 











at visit 2 (follow-
up) 


































Table 3-3:Group mean retinal hemodynamic parameters at follow-up visit. 
Vessel diameter, blood velocity, log maximum-to-minimum ratio and blood flow as a function of 
group. A p< 0.05 is considered statistically significant. (* indicates significantly different from group 












There were no significant differences found within or between Group 2 or Group 3 in terms Δ in 
retinal hemodynamic parameters. 
Change (Δ) in 
terms of 


































Table 3-4: Magnitude of change in retinal hemodynamics from baseline to follow-up visit in 
patients with NPDR.   
The variable called “Δ” was defined as the difference between each retinal hemodynamic parameter at 
visit 1 and visit 2 in terms of arteriolar diameter, blood velocity, max: min velocity ratio and blood 










Figure 3-2:Group means at baseline and follow-up as a function of group.  
Change over time between baseline and follow-up of retinal hemodynamic parameters (diameter, 
blood velocity, max:min velocity ratio and blood flow) as a function of group. Group 2; patients with 










3.5.2 Baseline inflammatory and endothelial dysfunction marker levels 
Group mean baseline values for soluble markers of inflammation and endothelial dysfunction are 
described in Table 3-3 and illustrated in Figure 3-2. Both sICAM-1 and sE-selectin were significantly 
elevated as a function of group (ANOVA p=0.02 and p=0.04, respectively).  A post hoc Bonferroni 
test showed that Group 3 had significantly higher sICAM-1 and sE-selectin levels compared to Group 
1 (234.0 vs. 151.5 ng/ml, P=0.02 and 53.4 vs. 27.6 ng/ml, P<0.01, respectively). VCAM-1 and vWF 
antigen were not statistically different (ANOVA p=0.25) between groups. Hemoglobin A1c was 
significantly elevated across the groups (ANOVA p<0.01), with Group 3 having significantly higher 
hemoglobin A1c levels compared to Group 1 (7.9 vs. 5.6 % , P<0.01).  
 
 









































Table 3-5: Group mean and standard deviation of markers inflammation and endothelial 
dysfunction as a function of group.  
sICAM-1, sVCAM-1 and sE-selectin are markers of inflammatory activity, while vWF Ag is a marker 
of endothelial dysfunction. ICAM-1: Intercellular adhesion molecule type 1, VCAM-1: vascular cell 
adhesion molecule type 1, and vWF; von Willebrand factor antigen. (* indicates significantly different 






Figure 3-3: Box plots of inflammatory and endothelial dysfunction, markers as a function of 
group.  
The inflammatory markers are; soluble intracellular adhesion molecule type 1 (sICAM-1) (upper left), 
soluble vascular cell adhesion molecule type 1 (sVCAM-1) (upper right) and soluble E-selectin 
(bottom left). The endothelial dysfunctional marker is von Willebrand factor antigen (vWF) (bottom 
right). For each graph, the center of the box represents the group mean level, the limits of the box 
represent ±1 SE and the whiskers represent ±1 SD. An open circle represents outlier values. Group 1: 
































Table 3-6: Group mean and standard deviation of A1c and hs CRP as a function of group.  
hsCRP: high sensitivity C-reactive protein and A1c; glycosylated hemoglobin (* indicates significantly 





Figure 3-4: Box plots of hs CRP and A1c markers as a function of group.  
Hs CRP; high sensitivity C-reactive protein and A1c; glycosylated hemoglobin. For each graph, the 
center of the box represents the group mean level, the limits of the box represent ±1 SE and the 
whiskers represent ±1 SD. An open circle represents outlier values. Group 1: age matched controls, 




3.5.3 Bivariate Pearson correlations between baseline markers of 
inflammation/endothelial dysfunction and baseline retinal hemodynamics 
measurements 
Baseline (Visit 1). The relationships between each hemodynamic parameter and systemic markers of 
inflammation and endothelial dysfunction were examined using a bivariate Pearson correlation. There 
were no significant associations found between baseline markers of inflammation and baseline retinal 
hemodynamics across all groups. Pearson correlation coefficients between baseline blood markers 
and baseline retinal hemodynamics are found in Table 3-7.  
Type of 
Markers 








































































Table 3-7: Pearson correlation values (r) and statistical significance (p) between baseline levels 
of markers of inflammation/ endothelial dysfunction and baseline retinal hemodynamic 
parameters across the pooled group. 
Retinal hemodynamic parameters as a function of vessel diameter, blood velocity, blood flow and log 
maximum-to-minimum velocity ratio in the pooled group. Systemic markers are; soluble intracellular 
adhesion molecule type 1 (sICAM-1), soluble vascular cell adhesion molecule type 1 (sVCAM-1), 
soluble E-selectin and von Willebrand factor antigen (vWF). A significant correlation was taken at r>± 
0.30 and p<0.05 after Bonferroni correction. Maximum-to-minimum velocity ratio was log 
transformed to satisfy normality. (*indicates statistical significance). 
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3.5.4 Pearson correlation between baseline levels of inflammatory/endothelial 
dysfunction markers and change (Δ) in retinal hemodynamics over 6 month time 
Six months post baseline visit. Analysis of Δ (difference between visit 1 and visit 2) in retinal 
hemodynamic parameters was limited to type 2 diabetes patients with NPDR. Pearson coefficients 
between Δ in terms of retinal hemodynamics and baseline levels of inflammation/endothelial 
dysfunction markers across Groups 2 and 3 are in Table 3-8. Δ velocity was correlated with the 
baseline sICAM-1 (r=0.42, p=0.02) and A1c levels (r=0.37, p=0.04) in patients with NPDR.  
Additional correlations between baseline blood markers and change in retinal hemodynamics from 






























































































Table 3-8: Pearson correlation values (with associated p-values) between baseline levels of 
inflammatory/endothelial dysfunction markers and Δ in retinal hemodynamic parameters in 6 
months time among patients with NPDR in Study 1.  
Retinal hemodynamic parameters are taken as vessel diameter, blood velocity, blood flow and log 
maximum-to-minimum velocity ratio) in patients with NPDR. Systemic markers are; soluble 
intracellular adhesion molecule type 1 (sICAM-1), soluble vascular cell adhesion molecule type 1 
(sVCAM-1), soluble E-selectin and von Willebrand factor antigen (vWF). A significant correlation 
was taken at r>± 0.30 and p<0.05.  (*indicates statistical significance). Patients with NPDR include 
groups 2 and 3. Group 2; mild-to-moderate NPDR, Group 3: moderate-to-severe NPDR. 
 
The multiple regression analysis indicated that none of the independent variables was significant 
predictors of change in Δ velocity. Based on these results we conclude that sICAM-1 and A1c have 
weak predictive power for Δ velocity groups with NPDR. The relationship between Δ velocity and 





Figure 3-5: Scatter plot of baseline sICAM-1 levels and change (Δ) velocity in 6 months time 
across patients with NPDR.  
Each circle indicates a subject of group 2 (mild-to-moderate NPDR) while each square 
indicates subjects of group 3 (moderate-to-severe NPDR). sICAM-1; Soluble intercellular 










To the best of our knowledge, this is the first study to investigate the relationship between arteriolar 
retinal blood flow parameters and circulating markers of vascular inflammation and endothelial 
dysfunction in patients with increasing severity of NPDR. In our sample, we had characterized two 
changes that are related to early NPDR: 1) an increase in velocity pulse wave amplitude representing 
a loss of vessel compliance at the baseline and at the follow-up visit and 2) elevated levels of soluble 
adhesion markers (sICAM-1 and sE-selectin) indicating inflammatory activity. This study suggests 
that a decrease in vessel compliance may occur along with an increase in inflammatory activity in 
patients with increasing NPDR severity. Although sICAM-1 and A1c have weak predictive power for 
Δ hemodynamic parameters, there was a bi-variate association found between these markers and Δ 
velocity after 6-month time in patients with NPDR.  
 
The max:min velocity ratio has previously been shown to be sensitive to alterations in retinal 
hemodynamics in patients with diabetes (27). At visit 1 and visit 2, we found an increase in 
baseline maximum-to-minimum velocity ratio, indicating a loss in vessel compliance with 
increasing severity of NPDR. Previous reports from our lab also suggest that arteriosclerotic 
changes occur in subjects with increasing risk for DME development (17, 27). An increase in 
max:min velocity ratio was correlated with age, duration of diabetes and blood pressure but not 
with blood glucose. With decreased compliance in the retinal circulation, an increase in 
pulsatility is expected due to a lack of dampening of the pulse wave. Recent work from our 
laboratory has also demonstrated a reduced vascular reactivity in retinal arterioles to isocapnic 
hyperoxic provocation in type 2 patients with NPDR and DME (17). Loss of vascular reactivity 
and a reduced compliance of the retinal arterioles would support the findings of the current study. 
 
 74 
Moreover, arteriosclerotic features may relate to the increase in inflammatory activity. Leukocyte 
mediated basement membrane (BM) thickening is a morphological sign of diabetic atherogenesis 
(60). Overall, our observations support increased vessel rigidity in the retinal vascular bed in 
patients with increasing NPDR severity.  
 
Our results also demonstrated elevated vascular adhesion levels. We found that inflammatory 
activity was increased with increasing severity of NPDR. Vascular inflammatory markers sICAM-1 
and sE-selectin were significantly higher in the moderate-to-severe group compared to healthy 
controls. Other systemic markers sVCAM-1, hsCRP and vWF were not statistically different in 
patients with diabetes from those without (p=0.24, p=0.43 and p=0.69).  Our results were consistent 
with earlier studies that show that sICAM-1 is elevated in patients with increasing severity of NPDR 
and plays a crucial role in leukocyte adherence to the endothelium (31, 51, 66). The up-regulation of 
sICAM-1 in the diabetic vasculature links leukostasis to early stages of DR (31, 34, 36, 66).   This is 
thought to be enhanced by several stimuli including vascular endothelial growth factor (VEGF) (9, 30, 
33), advanced glycosylated end products (AGEs) (46, 51, 64)  and oxidative stress (12, 14, 29) via the release 
of pro-inflammatory cytokines like Tumor Necrosis Factor-alpha (TNF-α). Moreover, we found that 
the expression of sE-selectin was significantly higher in patients with moderate-to-severe NPDR 
compared to the control group.  Previous studies did not find a difference in serum sE-selectin levels 
in patients with NPDR compared to healthy controls (7, 35). However, sE-selectin is consistently 
elevated in the vitreous and serum samples of patients with PDR compared to healthy controls (3, 4). 
Although our results show that endothelial dysfunction marker vWF Ag was not different between 
groups, one earlier study reported an elevated vitreous concentration of vWF in type 2 diabetes 
subjects with DR (52). One of the reasons for these differences in findings could be a large biological 
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variation of circulating adhesion molecules and vWF. Since we are measuring systemic serum vWF, 
its expression is unlikely isolated to retinal endothelial cells. The expression of the vascular adhesion 
molecules may be derived from cells outside of the retinal cells, which may explain the discrepancy 
in reports. For this and previous studies, only one measurement is performed. Further investigation of 
serial measurements of inflammatory and endothelial dysfunction markers over time might help 
predict vascular inflammatory activity more accurately. Our results suggest that there were elevated 
vascular inflammatory levels of sICAM-1 and sE-selectin in patients with DR compared to controls.  
Elevated vascular inflammatory activity could play a role in the development arteriosclerotic 
characteristics in the vessels of patients with NPDR.   
 
Several past reports suggest that increases in leukocyte adhesion are a critical factor in early DR 
and leads to stagnation in retinal blood flow (33, 49). We did not find a significant correlation between 
baseline retinal hemodynamics and inflammatory or endothelial dysfunction markers across all 
groups. However, recent reports of retinal vein occlusion (RVO) patients with macular edema have 
found that vitreous ICAM-1 level is inversely related to retinal blood flow velocity in the perifoveal 
capillaries (53) and likely contributes to the development of RVO. In our study, we found no such 
correlation.  Our results found blood velocity (∆ velocity) to be worsened after 6 months time with an 
early elevation in baseline sICAM-1 levels (r=0.42, p=0.02) and A1c levels (r=0.37, p=0.04) in 
patients with NPDR.  After adjustment for all other variables (A1c, hsCRP and vWF), the relationship 
between Δ velocity, sICAM-1 and A1c disappeared. Firstly, this trend suggests that high levels of 
sICAM-1 were associated with greater disturbance in blood velocity from baseline.  The up-
regulation of sICAM-1 may induce hemodynamic disturbance in DR by accelerating change in retinal 
blood velocity. Leukostasis and the subsequent extravasations of leukocytes may relate to abnormal 
release of endothelial derived factors that modulate blood velocity.  The control of vascular tone is a 
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balance between local endothelial cell released vasoconstrictive and vasodilatory factors. For 
instance, endothelin-1 (ET-1) plays an important role in retinal vascular autoregulation via regulating 
vessel vasoconstriction (13, 57). A recent study shows that endothelin-1 (ET-1) levels are low in patients 
with NPDR compared to controls and increase in proliferative retinopathy (56). Endothelin-1 can bind 
to either ETA stimulating smooth muscle vasoconstriction, while ET-3 binds to ETB, which stimulates 
vasodilation. The increased change in blood velocity may relate to altered ET-1 levels that interact 
with ETA receptors minimizing the vasoconstrictive tone. Low ET-1 levels relate to vessel 
vasodilation that is a clinical feature of DR (40, 63). Secondly and not surprisingly, the progression of 
DR is observed following the institution of strict diabetic glycemic control (1, 2, 8). The analysis of 
several published studies show consistent results, suggesting that progression is likely associated with 
hemodynamic changes in the retinal circulation (23, 24). Overall, further work is required to investigate 
whether inhibition of sICAM-1 could be a target for future treatment and a possible surrogate end-
point is the preservation of retinal blood velocity.  
 
Alternatively, it is also likely that linear relationships do not exist. Since we are examining markers 
of inflammation and endothelial dysfunction systemically and hemodynamics in the retinal arterioles 
only represents a small portion of the entire body’s vasculature, it is can be argued that we would not 
find a strong relationship. Overall, it is important to identify that in our study both retinal arterial 
stiffness and inflammatory markers increased in the moderate-to-severe NPDR group compared to the 
controls.  The presence of these two important DR determining factors within the same sample group 
warrants further investigation. In addition, future work will aim to use aqueous samples to assay 
ICAM-1, VCAM-1 and E-selectin. This may provide further evidence to support vascular 
inflammation related to DR complications (65).  
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In conclusion, we found a significant bi-variate relationship between ∆velocity after 6-month 
time and sICAM-1 and A1c levels. Although both sICAM-1 and A1c were of no predictive value 
for hemodynamic parameters, there is evidence that these events are related with respect to their 
development in NPDR. This study is the first to characterize two important events which occur 
simultaneously in patients with increasing NPDR; 1) increased pulsatility of the velocity wave 
profile in the retinal arteriolar vasculature and 2) elevated vascular adhesion molecule sICAM-1 
and sE-selectin levels.  Blood flow dynamics, such as blood velocity, pulsatility and vascular 
regulation have been shown to change throughout the progression of DR. Therefore, there is 
value in further investigating any possible association between increased rigidity and leukostasis.  
The process of leukostasis and its affiliation to retinal hemodynamics is clearly complex and 
warrants further investigation.  Understanding whether adhesion molecules interplay with a 
disturbance in hemodynamics may lead to the generation of strategies that could target early 











Retinal Vascular Reactivity and Systemic Markers of Vascular 
Inflammation, Endothelial Dysfunction in Type 2 Diabetes 
4.1 Overview 
Purpose: The purpose of this study was to investigate in patients with type 2 diabetes and non-
proliferative
 
 DR (NPDR); 1) The concomitant disturbance of retinal vascular reactivity and systemic 
markers of vascular inflammation and endothelial dysfunction and 2) the associations between retinal 
vascular reactivity and systemic markers of vascular inflammation and endothelial dysfunction. 
Retinal vascular reactivity (VR) was assessed both in terms of vessel diameter, blood velocity, 
maximum-to-minimum velocity ratio and volumetric flow at baseline and in terms of change in VR 
over 6 months time in patients with non-proliferative diabetic retinopathy (NPDR).  
Method:  The sample comprised of 36 NPDR patients with type 2 diabetes and 10 age matched 
control subjects (mean age 55.4±11.9 y.o; 6M: 4F). Patients were divided into mild-to-moderate 
(Group 2) (n=22, mean age 61.1±8.8 y.o, 12M: 10F) or moderate-to-severe (Group 3) (n=14, mean 
age 61.7±11.2 y.o, 7M:7F) NPDR according to ETDRS criteria. Retinal VR was assessed in the 
supero-temporal arteriole using the Canon Laser Blood Flowmeter. At baseline (visit 1), a minimum 
of 6 measurements were taken to determine hemodynamic parameters. Then 6 additional 
measurements were taken during exposure to isocapnic hyperoxia. The difference between baseline 
and hyperoxic provocation was taken as a measure of retinal VR. These measurements were repeated 
after 6 months follow-up. Baseline blood samples were collected to derive levels of vascular 
inflammation and endothelial dysfunction; soluble intercellular adhesion molecule-1 (sICAM-1), 
soluble vascular cell adhesion molecule-1 (sVCAM-1), sE-selectin, C-reactive protein (hsCRP) and 
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von Willebrand factor antigen (vWF Ag). The baseline systemic markers of vascular inflammation 
and endothelial dysfunction were correlated with baseline and change in retinal VR over 6 month 
time and compared between and within groups.  
 
Results:  Of the total enrolled subjects, 14 mild-to-moderate NPDR (Group 2) (mean age 64.1±8.1 
y.o, 8M: 6F) and 7 moderate-to-severe NPDR (Group 3) (mean age 58.7±11.3 y.o, 3M: 4F) returned 
for vascular reactivity assessment after 6 months.  VR at visit 1 and visit 2 showed no significant 
differences in change in terms of vessel diameter, blood velocity, log max:min velocity ratio and 
blood flow between groups. There were no significant differences in the Δ VR in retinal 
hemodynamic parameters over 6 months time between Groups 2 and 3. However, compliance was 
found to be significantly reduced in patients of Group 3 compared to Group 2 (-0.4 vs. 0.1, t-test 
p<0.01).   
 
Both sICAM-1 and sE-selectin were significantly elevated as a function of group (ANOVA p=0.02 
and p<0.01, respectively).  A post hoc Bonferroni test showed that Group 3 had significantly higher 
sICAM-1 and sE-selectin levels compared to Group 1 (243.4 vs. 157.3ngml, P<0.01 and 57.0 vs. 29.3 
ng/ml, P<0.01, respectively).  A1c was significantly elevated across the groups (ANOVA p<0.01), 
with Group 3 having significantly than Group 1 (8.8 vs. 5.6 %, P<0.01).  
 
Multiple regression analysis found that vascular inflammatory and endothelial function markers had 
weak predictive power for Δ hemodynamic parameters. However, weak to moderate correlations were 
found in both baseline and in the disturbance of VR after 6-month time and markers of vascular 
inflammation and endothelial dysfunction across all groups. Specifically, baseline VR in blood 
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velocity weakly correlates with sE-selectin (r=0.31, p=0.04) across all groups while sVCAM-1 was 
associated with VR in terms of blood flow (r=-0.62, p<0.01) in patients with mild-to-moderate 
NPDR. The ∆ blood flow after 6 months was found to be weakly associated with sE-selectin (r=0.46, 
p=0.03) across all groups. Finally, the ∆ blood velocity after 6 month time was found to be 
moderately correlated with baseline vWF Ag level (r=-0.78, p=0.02).  
 
Conclusion: Overall, we demonstrated two important characteristics in early NPDR; 1) a disturbance 
in vascular reactivity in terms of compliance and 2) an increase in systemic markers of inflammation 
were found in patients with NPDR. Although systemic markers of vascular inflammation and 
endothelial dysfunction are not predictive of hemodynamic parameters, our study found moderate 
associations between baseline and disturbances in VR after 6 months time. Therefore, there is 




The retinal microcirculation is unique since it is able to regulate blood flow to meet the metabolic 
demand of the surrounding tissue.  Vascular reactivity (VR) is defined as the magnitude of change of 
hemodynamic parameters (vessel diameter, velocity, or flow) in response to provocative stimuli such 
as oxygen (O2) (12, 21, 38), cold stress (15, 52, 56) or light flicker (16, 17, 58). The retinal VR response is a non-
invasive measure of vascular regulation.  Not only is a disturbance of homeostatic retinal blood flow 
is an accepted marker of early diabetic retinopathy (DR) (24) but there is also evidence of impaired VR 
in patients with non-proliferative diabetic retinopathy (NPDR).  Impaired vascular function has been 
shown to occur in patients with an increasing risk for diabetic macular edema (DME) development (19, 
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23, 24, 40). With the aid of respiratory physiology experts, our laboratory has developed a standardized 
isocapnic hyperoxic stimulus to evaluate the VR of retinal vessels. This technique has proven to be a 
reliable sensitive method to assess retinal VR (21). Although the exact mechanism of response to 
elevated arterial oxygen (pO2) is unclear, endothelium derived vasoactive factors such as nitric oxide 
(NO) and endothelin-1 (ET-1) may be primary in modulating retinal vascular reactivity. Endothelial 
cell dysfunction is an important determinant of altered VR and plays a major role in the genesis of 
both micro- and macrovascular complications in diabetes (4, 27, 50).  
 
Leukocyte-endothelial interaction plays an important role in the early development of DR (30, 46, 47, 
55, 60). A component of DR is a low-grade chronic inflammation associated with increased leukocyte 
entrapment in the retinal vasculature (3). The vascular inflammatory process, termed leukostasis, is 
secondary to the enhanced expression of soluble adhesion molecules (3, 30, 57, 60). These inflammatory 
mediators include soluble intercellular adhesion molecule (sICAM-1) (41, 44), vascular cell adhesion 
molecule (sVCAM-1) (36, 54, 60) and sE-selectin (39). Endothelial cell injury results in the expression of 
endothelial dysfunction marker von Willebrand factor antigen (vWF Ag), the up-regulation of which 
has also been found to be related to the severity of DR (6, 14).  
 
The purpose of this study was to investigate in patients with type 2 diabetes and non-
proliferative DR (NPDR): 1) The concomitant disturbance of retinal vascular reactivity and 
systemic markers of vascular inflammation and endothelial dysfunction; and 2) The associations 
between retinal vascular reactivity and systemic markers of vascular inflammation and 
endothelial dysfunction. Retinal VR was assessed both in terms of vessel diameter, blood 
velocity, maximum-to-minimum velocity ratio and volumetric flow at baseline and in terms of 
change in VR over 6 months time in patients with non-proliferative diabetic retinopathy (NPDR). 
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Earlier studies have shown that circulating markers of vascular inflammation and endothelial 
dysfunction are associated with clinically visible signs of DR (61). However, the association 
between vascular inflammatory activity and retinal vascular function in early DR has not been 
investigated.   Increased inflammatory activity may have modulating effects on VR.  Therefore, 
we hypothesize that baseline parameters of arteriolar VR are negatively correlated with systemic 
markers of vascular inflammation and endothelial dysfunction in type 2 diabetes. If a relationship 
can be shown to exist between circulating markers of inflammation and/or endothelial 
dysfunction and retinal vascular reactivity then the measurement of retinal vascular function can 
be utilized as a surrogate marker of vascular health.  
4.3 Materials and Methods 
4.3.1 Sample 
The sample comprised of 10 non-diabetes control subjects (Group 1) (6 M: 4 F, mean age of 55.4 ± 
11.9 years), 22 mild-to-moderate NPDR subjects (Group 2) (12M:10F, mean age of 61.1± 8.8 years), 
14 moderate-to-severe NPDR subjects (Group 3) (7 M: 7 F , mean age of 61.7 ± 11.2 years) (see 
Table 4-1).  
 
All volunteers were between the ages of 35 and 75 years and had a logarithm of the minimum 
angle of resolution (log MAR) visual acuity of 0.30, or better. Subjects were excluded from the 
study if they had a refractive error greater than ±6.00 DS and/or ±2.5 DC, ocular disease or 
disorder (other than evidence of DR), and a history of ocular surgery. Participants with nuclear 
opalescence, nuclear colour and posterior subcapsular cataract greater than 3, and cortical 
cataract greater than 2, as defined by the Lens Opacity Classification System III, were also 
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excluded (9). Subjects taking medications with known affects on blood flow (except for well-
controlled systemic hypertension) or who had known rheumatologic diseases were excluded from 
the study. To eliminate the confounding effect of vasoactive medications that affect blood flow 
(e.g. beta-blockers), all hypertensive medications were kept constant throughout the study. 
Control subjects were excluded from the study if there was an existing or history of diabetes 
and/or glaucoma in a first-degree relative. The glaucoma exclusion criterion was also applied to 
the diabetic patient groups.  
 
This study was approved by the University of Waterloo Office Of Research Ethics and the 
University Health Network Research Ethics Board, Toronto. Informed consent was obtained 
from each participant after thorough explanation of the nature of the study and its possible 




















1 n/a 10 55.4  
(11.9) 
















3 7:7 8.8 
(3.4) 
Table 4-1: Demographic details of the baseline study sample. 
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Sample size per group (n), group mean age (standard deviation, SD), known duration of diabetes 
(years), number (#) using insulin treatment, male: female, and glycosylated hemoglobin (A1c) as a 
function of group.  
4.3.2 Methodology 
Each volunteer underwent assessment to establish the overall DR status and a general health profile 
screening to determine study eligibility. This assessment included contact lens stereo fundus 
biomicroscopy, binocular indirect ophthalmoscopy and digital stereo fundus photography (Canon CR-
DGi with a 12.8 megapixel DSLR back; Canon, Tokyo Japan). One eye of each eligible patient was 
randomly assigned to the study. Prior to dilation with 1% tropicamide (Alcon Canada Inc), refraction, 
log Mar visual acuity, intraocular pressure and resting blood pressure (Omron HEM-907, 
IntellisenseTM) were all assessed. All volunteers underwent topic anesthesia (Alcaine; Alcon, 
Mississauga, Canada) prior to intraocular pressure (IOP) measurement using Goldmann applanation 
tonometry. Following pupil dilation and fundus photography, assessment of the presence and severity 
of lens opacity was undertaken. Volunteers were allocated into groups according to their retinal status 
defined using dilated stereo fundus biomicroscopy. Participants were categorized into two groups 
based on their risk factors for progression of DR: mild-to-moderate (Group 2) or moderate-to-severe 
NPDR (Group 3). Axial length data of the study eye was acquired using the I3 System ABD A-scan 
ultrasound (I3 Innovative Imaging Inc, Sacramento, CA).  
4.3.2.1 Quantitative Assessment of Retinal Arteriolar Vessel Diameter, Centerline Velocity 
and Blood Flow  
Non-invasive retinal arteriolar blood flow was quantified using the laser Doppler velocimetry and 
simultaneous vessel densitometry technique as incorporated into the Canon Laser Blood Flowmeter 
model 100 (CLBF: Canon, Tokyo, Japan). The technique and instrument has been described in detail 
in Chapter 1 and in Chapter 3. Using the CLBF, absolute measurements of vessel diameter (µm), 
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velocity (mm/s) and flow (µl/min) are obtained (For technical summary see Kida et al., 2002 (37); 
Canon, 1997). The method has been described extensively in detail in previous publications (18, 19, 22, 24, 
26). 
4.3.2.2 Isocapnic Hyperoxic Gas Delivery System 
In order to establish an isocapnic hyperoxic provocation, subjects were fitted to a silicon facemask 
that was made up of a fresh gas reservoir and an expiratory gas reservoir (Hi-OxSR, 
ViasysHealthcare, Yorba Linda, CA). The mask was designed such that the two separate inspiratory 
and expiratory limbs were connected by a single positive end-expiratory pressure (PEEP valve), 
allowing exhaled gas to be re-breathed as inhaled limb was depleted. The sequential re-breathing 
circuit allows for the manual manipulation of inspired and, consequently, expired gases. The rates of 
each air and oxygen flow were controlled using standard rotometers as flowmeters (Flowmeter 
56073-11-01-000, Controls corp. of America, Virginia beach, Virginia). This method is described in 
previous publications from our lab (22) in the investigation of vascular reactivity in both healthy and 
diseased eyes (18, 20-22, 62-64).  
 
4.3.3 Procedures 
At study visit 1, all volunteers had undergone an eligibility screening, group assignment, baseline 
retinal VR assessment and blood work. Prior to the VR assessment, each subject until heart rate and 
blood pressure were stabilized and then measurements were acquired. Subjects were fitted to the 
sequential re-breathing circuit (Hi-Ox SR, Viasys Healthcare, Yorba Linda, Ca). The circuit was 
comprised of a non-rebreathing valve, a fresh gas and a rebreathing as reservoir, which are connected 
to the gas supply. In the administration of air for the first 10 minutes, subjects were instructed to 
breath at a steady rate until a stable resting concentration of CO2
 
in the expired breath  (PETCO2) of 
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38mmHg (± 2 mmHg) and a concentration of O2
 
in the expired breath PETO2 of 16% was reached. 
Tidal gas concentrations were measured continuously. Blood pressure was monitored every 2.5 
minutes while pulse rate and oxygen saturation was measured every minute during the breathing 
period using a rapid response critical care gas analyzer (Cardiocap 5, Datex-Ohmeda, Helsinki, 
Finland). Once stabilized, 6 good quality CLBF measurements were acquired to determine vessel 
diameter, blood velocity and blood flow at a chosen site of the study eye. The site of CLBF 
measurement was approximately 1 disc diameter distant from the edge of the optic nerve head along a 
relatively straight segment of the supero-temporal arteriole and distant from any bifurcations. In the 
following isocapnic hyperoxic breathing stage, PETO2 was increased to 100% while maintaining a 
stable resting PETCO2 of 38mmHg (±2mmHg). During this next phase, 6 additional CLBF 
measurements were acquired. VR was quantified as the magnitude of change from baseline (air) to 
the isocapnic hyperoxia in terms of retinal arteriolar diameter, blood velocity, maximum: minimum 
velocity ratio and blood flow. At visit 2, VR measurements were taken using the CLBF at the 
identical arteriole site as in visit 1.  
4.3.3.1 Isolating Soluble Markers of Inflammation and Endothelial Dysfunction 
Forearm blood sample was collected at visit 1 after retinal VR assessment for each patient. For 
vascular inflammatory markers sICAM-1, sVCAM-1 and sE-selectin, blood was collected into a 7 ml 
heparin vacutainer and plasma was obtained by centrifugation. The plasma sample was then separated 
into polystyrene tubes in 4 equal amounts (one sample tube for each marker plus an additional sample 
if a test was to be repeated) and stored at -80oC until assayed. Plasma samples were determined using 
standard, validated techniques via enzyme-linked immuno-sorbent assay methods (R&D Systems, 
Minneapolis, MN). Standard ELISA sandwich enzyme immuno-assay technique was applied and 




Blood samples were also collected at baseline from all patients with diabetes and controls for the 
quantitative determination of von Willebrand factor antigen (vWF Ag), a marker of endothelial 
dysfunction, in plasma and assessed with an immuno-turbidimetric assay (STA-Liatest vWF, 
Diagnostica Stago, France). (see Appendix A).  
 
In terms of the manufacturers reported reproducibility, the coefficient of variation (COV) of 
sICAM-1, sVCAM-1 and sE-selectin was found to be between 2.3-6.6% for intra-assay precision 
(tested twenty times) and COV of 4.4-7.8% for inter-assay precision (tested forty times) (R&D 
Systems, Minneapolis, MN). 
4.4 Analysis 
4.4.1 Blood Flow Data 
Axial length and refractive error data of each study eye was used to correct CLBF measurements for 
magnification effects. A post-acquisition analysis of the velocity waveforms were performed using a 
standardized laboratory protocol to remove aberrant waveforms affected by eye movements, tear film 
breakup, or improper tracking of the measurement laser. Velocity waveforms were accepted if there 
was a minimum of one complete cardiac cycle which was not adversely affected by major eye 
movements, i.e. more than 25 μm in each direction.  
4.4.2 Evaluation of disturbance in vascular reactivity over 6 months  
“Δ” was defined as the difference between vascular reactivity at visit 1 and visit 2 in terms of 
arteriolar diameter, blood velocity, max: min velocity ratio and blood flow.  A worsening of vascular 
reactivity response in visit 2 compared to visit 1 was assigned a negative value (-).  
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4.4.3 Statistical Analysis 
The normality for all variables as a function of group was confirmed to satisfy the use of parametric 
statistics. All parameters followed a normal distribution, except for the maximum-to-minimum 
velocity ratio that was then log transformed in order to satisfy normality. A One-way ANOVA was 
used to determine differences in VR between groups at baseline and at visit 2. For all significant one-
way ANOVAs, Bonferroni corrections were used in order to reduce Type I experimental errors. 
The Δ VR parameters between Group 2 and Group 3 were tested using paired t-tests. The dependant 
variables were diameter, velocity maximum-to-minimum velocity ratio and blood flow. The 
within subject factor was isocapnic hyperoxia and the between subject factor was group. The 
results of sICAM-1, sVCAM-1, sE-selectin and vWF were represented using box-plots. The 
magnitude of VR at baseline and ΔVR over 6 months time for each of the hemodynamic parameters 
in each group was correlated with baseline sICAM-1, sVCAM-1, sE-selectin, vWF Ag, hs CRP and 
A1c values using bivariate Pearson correlation. A Pearson correlation coefficient value of r>0.3 and 
p<0.05 was considered statistically significant. All significant correlations were then entered into 
a multiple regression model to determine if any of the significant factors were predictive of the 
dependent variable (a given hemodynamic parameter).  
4.5 Results 
Of the total subjects enrolled in the study, 21 patients with diabetes returned for follow-up assessment 
6 months later, comprising  14 mild-to-moderate NPDR subjects (Group 2) (8M: 6F, mean age of 
64.1 ± 8.1years) and 7 moderate-to-severe NPDR subjects (Group 3) (3M: 4F, mean age of 58.7 ± 
11.3 years).  
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4.5.1 Baseline (visit 1) and follow-up (visit 2) vascular reactivity response 
VR at visit 1 showed no significant differences in mean values in terms of vessel diameter, blood 
velocity, log maximum-to-minimum velocity ratio and blood flow between groups (see Table 4-2). 
Figure 4-1 illustrates the VR response to the standardized isocapnic hyperoxic stimulus at visit 1 for 
all retinal hemodynamic parameters.  
 
Mean VR 
response at    
visit 1 in terms of 




 n=10 n=22 n=14  
Diameter  
(µm) 
-3.9 (4.9) -2.4 (5.8) -0.7 (6.2) 0.41 
Velocity 
(mm/sec) 
-9.7 (3.0) -10.4 (6.6) -9.9 (7.3) 0.96 
Flow 
(μL/min) 
-2.4 (2.0) -3.4 (2.3) -2.8 (2.8) 0.54 
Log Max:Min 
Ratio 
0.05 (0.2) 0.07 (0.2) 0.09 (0.1) 0.79 
Table 4-2: Group mean vascular reactivity in terms of retinal hemodynamic parameters to a 
standardized isocapnic hyperoxic stimulus at visit 1.  
Retinal hemodynamics in terms of vessel diameter, blood velocity, log max:min velocity ratio and 
blood flow. Statistical significance are assumed when p<0.05. Group 1; age-matched control, Group 2; 






Figure 4-1: Box plots of vascular reactivity in retinal hemodynamic parameters in response to 
an isocapnic hyperoxic stimulus a function of group at visit 1.  
Arteriolar vessel diameter (upper left), blood velocity (upper right), blood flow (bottom left) and log 
maximum-to-minimum velocity ratio (bottom right). For each graph, the center of the box represents 
the group mean, the limits of the box represent ±1 SE and the whiskers represent ±1 standard 
deviation. Each point represents an outlier. Group 1; age-matched control, Group 2; mild-to-moderate 
NPDR, Group 3: moderate-to-severe NPDR. 
 
VR at follow-up (visit 2) also showed no significant differences in change in terms of vessel diameter, 
blood velocity, maximum-to-minimum velocity ratio and blood flow between Groups 2 and 3 (see 
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Table 4-3: Group mean vascular reactivity (VR) in terms of retinal hemodynamic parameters 
to a standardized isocapnic hyperoxic stimulus at visit 2.  
Retinal hemodynamics in terms of vessel diameter, blood velocity, log max:min velocity ratio and 
blood flow. Statistical significance are assumed when p<0.05. Group 1; age-matched control, Group 2; 





Figure 4-2: Box plots of vascular reactivity in retinal hemodynamic parameters in response to 
an isocapnic hyperoxic stimulus a function of group at visit 2.  
Arteriolar vessel diameter (upper left), blood velocity (upper right), blood flow (bottom left) and log 
maximum-to-minimum velocity ratio (bottom right). For each graph, the center of the box represents 
the group mean, the limits of the box represent ±1 SE and the whiskers represent ±1 standard 










4.5.2 Change in vascular reactivity response (ΔVR) over 6 month time 
Δ max:min velocity ratio (compliance) was found to be significantly reduced in Group 3 patients 
compared to Group 2 (-0.4 vs. 0.1, t-test p<0.01) (See Figure 4-3).  There were no significant 
differences in the mean ΔVR (VR difference between visit 1 and visit 2) in terms of arteriolar 
diameter, blood velocity and flow between Groups 2 and 3 (see Table 4-4).  
 
Mean ΔVR in 
terms of 
Group 2 Group 3 t-test 
p-value 




























Table 4-4: Mean Δ vascular reactivity in terms of retinal hemodynamic parameters as a function of 
group. 
Retinal hemodynamics in terms of vessel diameter, blood velocity, log max:min velocity ratio and 
blood flow. An impaired ΔVR response in visit 2 compared to visit 1 was assigned a negative value (-), 
indicating direction of change. Statistical significance are assumed when p<0.05. Group 2; subjects 




Figure 4-3: Box plots of change in vascular reactivity (ΔVR) from visit 1 to visit 2 (6 month 
follow-up) in terms of retinal hemodynamic parameters.  
Retinal hemodynamic parameters include arteriolar vessel diameter (upper left), blood velocity (upper 
right), blood flow (bottom left) and log maximum-to-minimum velocity ratio (bottom right). For each 
graph, the center of the box represents the group mean level, the limits of the box represent ±1 SE and 
the whiskers represent ±1 SD. Each point indicates outliers. Group 2; mild-to-moderate NPDR, Group 






4.5.3 Baseline levels of inflammation and endothelial dysfunction markers 
Baseline group mean levels of inflammation and endothelial dysfunction are defined below (see Table 
4-5), and are illustrated in terms of box-plot distributions in Figure 4-4. Both sICAM-1 and sE-
selectin were significantly elevated as a function of group (ANOVA p=0.02 and p<0.01).  A post hoc 
Bonferroni test showed that Group 3 had significantly higher sICAM-1 and sE-selectin levels 
compared to Group 1 (243.4 vs. 157.3ngml, P<0.01 and 57.0 vs. 29.3 ng/ml, P<0.01, respectively). 
sVCAM-1 and vWF Ag was not significantly different between groups (ANOVA p=0.11 and p=0.49, 
respectively). A1c was significantly elevated in across the groups (ANOVA p=0.013) (see Table 4-6 
and Figure 4-5), with Group 3 having higher A1c levels compared to Group 1 (8.8 vs. 5.6 %, P<0.01).  
 
 










































Table 4-5: Group mean and standard deviation (SD) of markers inflammation and endothelial 
dysfunction as a function of group.  
sICAM-1, sVCAM-1 and sE-selectin are markers of inflammatory activity, while vWF Ag is a marker 
of endothelial dysfunction. sICAM-1: soluble intercellular adhesion molecule type 1, sVCAM-1: 
soluble vascular cell adhesion molecule type 1, and vWF Ag; von Willebrand factor antigen. (* 
indicates significantly different from group 1). Group 1; age-matched control, Group 2; mild-to-






Figure 4-4: Box plots of baseline levels of inflammation and endothelial dysfunction markers as 
a function of group.  
The inflammatory markers are; soluble intracellular adhesion molecule type 1 (sICAM-1) (upper left), 
soluble vascular cell adhesion molecule type 1 (sVCAM-1) (upper right) and soluble E-selectin 
(bottom left). The endothelial dysfunctional marker is von Willebrand factor antigen (vWF) (bottom 
right). For each graph, the center of the box represents the group mean level, the limits of the box 
represent ±1 SE and the whiskers represent ±1 SD. Each point represents an outlier values. Group 1: 

































Table 4-6: Group mean and standard deviation of A1c and hs CRP as a function of group.  
hsCRP: high sensitivity C-reactive protein and A1c; glycosylated hemoglobin (* indicates significantly 





Figure 4-5: Box plots of hs CRP and A1c markers as a function of group.  
Hs CRP; high sensitivity C-reactive protein and A1c; glycosylated hemoglobin. For each graph, the 
center of the box represents the group mean level, the limits of the box represent ±1 SE and the 
whiskers represent ±1 SD. An open circle represents outlier values. Group 1: age matched controls, 




4.5.4 Relationship between baseline (visit 1) VR and baseline levels of vascular 
inflammation and endothelial dysfunction 
Baseline (Visit 1). The relationships between each hemodynamic aspect of baseline VR and systemic 
markers of vascular inflammation and endothelial dysfunction were examined using a bivariate 
Pearson correlation. Results showed that VR in terms of velocity was weakly associated with sE-
selectin (r=0.31, p=0.04). Otherwise, there were no significant associations found between baseline 
VR in terms of diameter, blood flow and max:min velocity ratio and baseline levels of vascular 
inflammation and endothelial dysfunction across all group (Table 4-7). 
Type of 
marker 













































































Table 4-7: Pearson correlation coefficients (r) and statistical significance (p) between markers 
of inflammation/endothelial dysfunction and baseline vascular reactivity (VR) in retinal 
hemodynamics ratio across all groups.  
Retinal hemodynamic parameters as a function of vessel diameter, blood velocity, blood flow and log 
maximum-to-minimum velocity ratio in the pooled group. Systemic markers are; soluble intracellular 
adhesion molecule type 1 (sICAM-1), soluble vascular cell adhesion molecule type 1 (sVCAM-1), 
soluble E-selectin and von Willebrand factor antigen (vWF). A significant correlation was taken at r>± 
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0.30 and p<0.05. Maximum-to-minimum velocity ratio was log transformed to satisfy normality. 
(*indicates statistical significance). 
 
Multiple regression analysis found that none of the independent variables were significant predictors 
of change in VR in velocity. Based on these results we conclude that sE-selectin was weakly 
correlated with VR in terms of velocity across all groups (Figure 4-6).  
 
Figure 4-6: Scatter-plot of baseline vascular reactivity in blood velocity and baseline sE-selectin 
across all groups.  
Each triangle represents subjects from Group 1 (healthy controls), circle represents subjects from 
Group 2 (mild-to-moderate NPDR), while each square represents subjects from Group 3 (moderate-to-




Considering the likelihood of differing levels of inflammatory and endothelial dysfunction activity 
specific to each stage of DR, we explored possible correlations within each of Groups 2 and 3. There 
were no significant correlations in Group 3. A moderate inverse association was revealed between the 































Table 4-8: Pearson correlation coefficients (r) and statistical significance (p) between markers 
of vascular inflammation/endothelial dysfunction and baseline vascular reactivity in blood flow 
in group 2 
 
Multiple regression analysis indicated that none of the independent variables were significant 
predictors of change in VR in terms of blood flow. Based on the results we conclude that sVCAM-1 
has weak predictive power for VR in blood flow in patients with mild-to-moderate NPDR but still 
shows moderate correlation.  
                            
                                          
4.5.5 Bivariate Pearson correlations between change in vascular reactivity (ΔVR) and 
baseline levels of vascular inflammation and endothelial dysfunction 
Pearson coefficients between ΔVR in terms of retinal hemodynamics and change in levels of vascular 
inflammation and endothelial dysfunction markers across Groups 2 and 3 are in Table 4-9. Our results 


















































































Table 4-9: Pearson correlation coefficients (r) and statistical significance (p) between markers 
of inflammation/endothelial dysfunction and Δ VR in hemodynamic parameters in patients with 
NPDR.  
Retinal hemodynamic parameters are taken as vessel diameter, blood velocity, blood flow and log 
maximum-to-minimum velocity ratio) in patients with NPDR. Systemic markers are; soluble 
intracellular adhesion molecule type 1 (sICAM-1), soluble vascular cell adhesion molecule type 1 
(sVCAM-1), soluble E-selectin and von Willebrand factor antigen (vWF). A significant correlation 
was taken at r>± 0.30 and p<0.05.  Group 2; mild-to-moderate NPDR, Group 3: moderate-to-severe 
NPDR (*indicates statistical significance). 
 
Multiple regression analysis showed that none of the independent variables were significant 
predictors of change in blood blow. Based on these results, we conclude that sE-selectin has weak 
predictive power for Δ blood flow across all groups but is weakly correlated.  
 
Similar to the previous section we considered the likelihood of differing levels of inflammatory 
and endothelial dysfunction activity specific to each stage of DR, we explored possible correlations 
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within each Groups 2 and 3. There were no significant correlations in Group 2. A moderate inverse 
association was revealed between the Δ velocity and vWF (r=-0.78, p=0.02) in subjects of Group 3 

































Table 4-10: Pearson correlation coefficients (r) and statistical significance (p) between Δ 
velocity and markers of inflammation/endothelial dysfunction in patients with moderate-to-
severe NPDR (Group 3).   
Retinal hemodynamic parameters are taken as vessel diameter, blood velocity, blood flow and log 
maximum-to-minimum velocity ratio) in patients with NPDR. Systemic markers are; soluble 
intracellular adhesion molecule type 1 (sICAM-1), soluble vascular cell adhesion molecule type 1 
(sVCAM-1), soluble E-selectin and von Willebrand factor antigen (vWF). A significant correlation 
was taken at r>± 0.30 and p<0.05.  Group 3: moderate-to-severe NPDR (*indicates statistical 
significance). 
 
Multiple regression analysis showed that none of the independent variables were significant 
predictors of Δ blood velocity. Based on these results we conclude that vWF has weak predictive 
power for Δ velocity in patients with moderate-to-severe NPDR but are moderately correlated. The 






Figure 4-7: Scatter plot of the change in vascular reactivity from visit 1 to visit 2 in terms of 
blood velocity and von Willebrand factor antigen in patients moderate-to-severe NPDR (Group 
3).  
 
Overall, multiple regression analysis showed that none of the independent variables were 
significant predictors of Δ vessel diameter, blood velocity, max:min velocity ratio or blood flow. 
Based on these results, we conclude that the vascular inflammatory and endothelial function markers 
have weak predictive power for Δ hemodynamic parameters in patients with mild-to-moderate and 





This is the first study to investigate the association between vascular inflammatory and endothelial 
dysfunction markers and retinal vascular reactivity in patients with increasing severity of NPDR. In 
our sample, we had characterized two changes that are related to early NPDR: 1) a greater increase in 
vascular rigidity and reduced vascular reactivity after 6 months follow-up; and 2) elevated levels of 
soluble adhesion markers (sICAM-1 and sE-selectin) indicating inflammatory activity. This study 
suggests that vessel compliance may occur along with elevated inflammatory levels in patients with 
increasing NPDR severity. Although vascular inflammatory and endothelial function markers have 
weak predictive power for Δ hemodynamic parameters, weak to moderate significant correlations 
were found in both baseline and in the disturbance of vascular reactivity (ΔVR) after 6 month time 
and markers of inflammation and endothelial dysfunction across all groups. Specifically, baseline VR 
in blood velocity weakly correlates with sE-selectin (r=0.31, p=0.04) across all groups while 
sVCAM-1 is associated with VR in terms of blood flow (r=-0.62, p<0.01) in patients with mild-to-
moderate NPDR. The ∆ in blood flow after 6 months  was found to be weakly associated with sE-
selectin (r=0.46, p=0.03) across all groups. Finally, the ∆ velocity after 6 month time was found to be 
moderately correlated with baseline vWF level (r=-0.78, p=0.02). Therefore, both inflammatory 
activity and endothelial dysfunction may be related to abnormal retinal vascular function. 
 
Abnormal macro and microvascular vascular reactivity response in patients with DR are well 
established (5, 18, 42). There was no significant difference in VR in visit 1 or 2 across all groups.  In 
a recent study using the standardized isocapnic hyperoxic stimulus, VR in patients with early 
sight threatening DR was found to be significantly reduced with increasing severity of early DR 
and sight threatening DME (18). Physiologically, retinal blood flow varies inversely with the 
partial pressure of arterial oxygen (PO2) to maintain retinal oxygenation at a relatively constant 
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level. In our study, although the magnitude of response in vessel diameter, velocity and flow 
were not significantly different between groups, the response tended to be impaired with 
increasing severity of NPDR. The lack of significance is likely because our sample was not 
sufficient but this never was an aim of the study.  
 
Although functional hemodynamic indices such as maximum-to-minimum velocity ratio, and 
wall shear rate have been previously studied in DR (24, 51, 53), few other studies have examined the 
change in retinal vascular reactivity response over time. Results from this study show that 
patients with moderate-to-severe NPDR exhibited a greater increase in vascular rigidity and 
reduced vascular reactivity over time than those with mild-to-moderate NPDR. Recent work has 
also demonstrated a reduced compliance in type 2 patients with NPDR and DME (25).  Loss of 
vascular reactivity and a reduced compliance of the retinal arterioles with increasing severity of 
DR would explain these results and support the findings of the current study. In support of this, 
some conditions including aggravation of vascular risk factors and progression of 
arteriosclerosis, lead to vessel wall remodeling and greater vessel rigidity over time. Overall, this 
indicates an inability to increase vessel tonus in response to isocapnic hyperoxic provocation in 
patients with moderate-to-severe NPDR.  
 
Our results also demonstrated elevated vascular adhesion levels in our cohort. We found that 
inflammatory activity was increased with increasing severity of NPDR. Inflammatory markers 
sICAM-1 and sE-selectin were significantly higher in the moderate-to-severe group compared to 
healthy controls. Other systemic markers sVCAM-1, hsCRP and vWF were not statistically 
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different in patients with diabetes from those without (ANOVA p=0.11, p=0.35 and p=0.49).  
Our results were consistent with early studies, which show that sICAM-1 is elevated in patients 
with increasing severity of NPDR and plays a crucial role in leukocyte adherence to the 
endothelium (3, 30, 57, 60).  The up-regulation of sICAM-1 in the diabetic vasculature links 
leukostasis to early stages of DR (30, 32, 33, 60).   This is thought to be enhanced by several stimuli 
including vascular endothelial growth factor (VEGF) (8, 29, 31), advanced glycosylated end 
products (AGEs) (43, 48, 59)  and oxidative stress (10, 13, 28) via the release of pro-inflammatory 
cytokines like Tumor Necrosis Factor-alpha (TNF-α) (34). Moreover, we found that the expression 
of sE-selectin was significantly higher in patients with moderate-to-severe NPDR compared to 
the control group.  The majority of previous studies did not find a difference in serum E-selectin 
levels in patients with NPDR compared to healthy controls (7, 32). However, E-selectin is 
consistently elevated in the vitreous and serum samples of patients with PDR compared to 
healthy controls (1, 2).  
 
We found that endothelial dysfunction marker vWF Ag was not different between groups, 
however, there was one earlier study that reported an elevated vitreous concentration of vWF in 
type 2 diabetes subjects with DR (49). One of the reasons for these differences in findings could be 
a large biological variation of circulating adhesion molecules and vWF. Since we are measuring 
serum vWF Ag, its expression is unlikely isolated to retinal endothelial cells. The expression of 
the vascular adhesion molecules may be derived from cells outside of the retinal cells, which may 
contribute to the discrepancy in reports. For this and previous studies, only one measurement is 
performed. Further investigation of serial measurements of inflammatory and endothelial 
dysfunction markers over time might help predict inflammatory activity more accurately. Our 
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results suggest that there were elevated inflammatory levels of sICAM-1 and sE-selectin in 
patients with diabetic retinopathy compared to controls.  Elevated inflammatory activity could 
play a role in the development arteriosclerotic characteristics in the vessels of patients with 
NPDR.   
 
We found significant relationships between baseline VR and systemic markers of vascular 
inflammation and endothelial dysfunction. Results indicate that VR in terms of velocity was 
weakly associated with sE-selectin (r=0.31, p=0.04) across all patients and low VR in terms of 
blood flow is correlated to high sVCAM-1 levels (r=-0.62, p<0.01) in mild-to-moderate NPDR. 
This finding suggests a possible pro-inflammatory role of sE-selectin and sVCAM-1 in 
compromising retinal endothelial cell integrity. After adjustment for all other variables (A1c, 
hsCRP and vWF), the predictive power of this correlation was found to be negligible.  At the 
cellular level, both sE-selectin and sVCAM-1 have been shown to exert pro-inflammatory 
properties by promoting leukocyte adhesion, likely via the NFk-B pathway (45, 48). Considering 
the expression of these markers by vascular endothelial cells throughout the body and assuming 
that DR is a state of chronic vascular inflammation, sE-selectin and sVCAM-1 are not likely to 
represent a molecular link between metabolic signals, vascular inflammation and vascular 
dysfunction specifically to DR.  
 
Our study report a correlation between disturbance of VR in terms of blood velocity (Δ 
velocity) over 6-months follow-up and baseline vWF level in patients with moderate-to-severe 
NPDR (r=-0.78, p=0.02). This suggests that a disturbance in blood velocity is associated with 
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lower levels of vWF. After adjustment for all other variables (A1c, hsCRP and vWF), the 
predictive power of this correlation was found to be negligible.  The analysis of several published 
studies show consistent results, thus, the presence of impaired endothelial function does not 
demonstrate elevated vWF levels in diabetic retinopathy (42).  As retinal blood flow represents 
only a small part of the total blood flow in the body, it is also unlikely that high systemic vWF 
levels could result from increased production in the retinal endothelium at a single measurement. 
Although we only found a bi-variate correlation between vWF and VR, there are many studies 
that suggest that vWF favourably affects endothelial function and vascular homeostasis (6, 11, 49). 
Elevations in plasma vWF in persons with diabetes are believed to reflect functional and 
structural changes in the vascular endothelium (35). Further studies are needed to address whether 
intervention that decreases vWF levels can improve endothelial function and reduce clinical signs 
of NPDR.  
 
Overall, although we only found weak to moderate bi-variate correlations between endothelial 
dysfunction, vascular inflammation and retinal vascular function in early NPDR, a common 
denominator of microvascular complications is thought to involve impaired nitric oxide synthesis 
and the generation of inflammatory state. A recent study by Patel and colleagues found that 
hemodynamic related marker endothelin-1 (ET-1) and anti-inflammatory cytokine IL-1 Ra are 
low in patients with NPDR (57). In this environment, ET-1’s vasoconstrictive effect would be 
minimal. This potential relationship supports the hypothesis, set up by other authors (10) that 
vascular inflammation is the primary process in endothelial dysfunction resulting in reduced 




In conclusion, we found significant bi-variate relationships between baseline VR and in the 
disturbance of VR after 6 month time and markers of inflammation and endothelial dysfunction 
across all groups. However, these were of no predictive value for hemodynamic parameters. Overall, 
this study is the first to characterize two important features that are present in patients with increasing 
NPDR; 1) tendency for impaired vascular reactivity and reduced compliance in the retinal arteriolar 
vessel; and 2) increased levels of sICAM-1 and sE-selectin. Elevated inflammatory adhesion 
molecules in early NPDR may disturb vascular function, possibly mediated through smooth muscle 
cell dysfunction as well as endothelial dysfunction. The mechanism of leukostasis and its affiliation to 
a loss of vascular reactivity in the retinal microcirculation is clearly complex and deserves further 
investigation.  Understanding whether adhesion molecules interplay with endothelial dysfunction in 
producing vascular dysregulation may lead to the generation of strategies that could target early 


















Studies have shown that altered retinal blood flow and vascular regulation and elevated vascular 
inflammatory activity are both involved in the pathogenesis of early diabetic retinopathy (DR)(5-7, 9, 10, 
16-18).  A loss of vasoconstrictive capacity of the retinal vasculature to a hyperoxic stimulus has been 
established (2-4, 8). Increased levels of systemic vascular inflammatory markers are found in persons 
with type 2 DR. Endothelial dysfunction is also found to be strongly associated with early DR in both 
type 1 and 2 diabetes(1, 11, 12, 15).  Earlier studies have shown abnormalities of blood flow parameters 
along with increased leukocyte adhesion in the retinal capillaries in animal models, suggesting that 
these changes may represent a precursor to any clinical findings (13, 14). Prior to this work, however, it 
was unknown whether abnormal retinal hemodynamics related to increasing vascular inflammatory 
activity or endothelial dysfunction in human NPDR. We have investigated the concomitant 
disturbance of retinal hemodynamics and retinal VR with systemic markers of vascular inflammation 
and endothelial dysfunction.  
 
This investigation of patients with type 2 diabetes with NPDR had two objectives: 
1) To investigate the concomitant disturbance of retinal blood flow hemodynamics and its 
association with systemic markers of vascular inflammation and endothelial dysfunction.  
2)  To investigate the concomitant disturbance of retinal VR and its association with systemic 






For the two objectives, we hypothesized: 
1) Baseline arteriolar hemodynamics and the magnitude of retinal hemodynamic 
disturbance over 6-month follow-up are positively correlated with systemic markers of 
vascular inflammation and endothelial dysfunction in type 2 diabetes.  
2) The magnitude of retinal VR at baseline and the disturbance of VR over 6-month follow-
up are positively correlated with systemic markers of vascular inflammation and 
endothelial dysfunction in type 2 diabetes.  
 
In answering the first objective (Chapter 3), retinal hemodynamics was assessed both in terms 
of vessel diameter, blood velocity, maximum-to-minimum velocity ratio and volumetric flow at 
baseline and in terms of change in hemodynamic parameters over 6 months time in patients with 
NPDR. Our results also show an increase rigidity of the arteriolar circulation at baseline and 
follow-up and an increase vascular adhesion markers sICAM-1 and sE-selectin within the same 
population sample. We also found that the Δ velocity over the follow-up period was correlated 
with sICAM-1 and A1c levels in patients with NPDR but the level of association was such that 
neither sICAM-1 nor A1c proved to reliably predict retinal hemodynamics. Results from this 
study support reduced retinal arteriolar compliance in conjunction with increased vascular 
inflammatory activity in patients with moderate-to-severe NPDR compared to healthy controls, 
suggesting a possible link between vascular inflammation and prospective increase in retinal 
vascular rigidity in early NPDR.  
 
In chapter 4, we investigated retinal vascular regulation and circulating systemic markers of 
inflammation and endothelial dysfunction. Retinal VR was assessed both in terms of vessel diameter, 
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blood velocity, maximum-to-minimum velocity ratio and volumetric flow at baseline and in terms of 
change in VR over 6 months time in patients with NPDR. Overall, we found reduced compliance 
after 6 months follow–up in the moderate-to-severe group compared to the mild-to-moderate group 
and concurrent elevated baseline levels of sICAM-1 and sE-selectin.  Moreover, results indicate a bi-
variate association between baseline VR in blood velocity with sE-selectin (r=0.31, p=0.04) across all 
groups while sVCAM-1 was associated with VR in terms of blood flow (r=-0.62, p<0.01) in patients 
with mild-to-moderate NPDR. The ∆ blood flow after 6 months was found to be weakly associate d 
with sE-selectin (r=0.46, p=0.03) across all groups. Finally, the ∆ blood velocity after 6 month time 
was found to be moderately correlated with baseline vWF Ag level (r=-0.78, p=0.02). However, after 
being entered into a multiple regression model, these vascular inflammatory and endothelial 
dysfunction markers were of no predictive value for any hemodynamic parameters. These results 
suggest a possible pro-inflammatory role that might be involved in retinal endothelial integrity. 
Elevated inflammatory adhesion molecules in early NPDR may disturb vascular function, possibly 
mediated through smooth muscle cell dysfunction as well as endothelial dysfunction. Although these 
markers show no predictive value in VR, results indicate that retinal vascular function might alter 
concomitantly with inflammatory activity in early NPDR. 
 
In conclusion, our study found 1) increased levels of sICAM-1 and sE-selectin along with 2) 
increased pulsatility or vessel rigidity in the retinal arteriolar vasculature at baseline and follow-
up and 3) a tendency for impaired vascular reactivity and reduced compliance in the retinal 
arteriolar vessel in early DR. These findings support early accelerated arteriosclerosis type 
changes and altered endothelial cell activity in mediating abnormal in RBF in early development 
of DR.  The mechanism of leukostasis and its possible relationship to a loss of VR in the retinal 
microcirculation is clearly complex and deserves further investigation.  Understanding whether 
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adhesion molecules interplay with endothelial dysfunction in producing vascular dysregulation 
may lead to the development of strategies that could target early abnormalities before clinically 
visible signs of DR are apparent.  
 
Future Studies 
Future work should investigate the concomitant disturbance in VR and vascular inflammatory activity 
over an extended longitudinal study design. It is of significance to understand whether prolonged 
exposure to hyperglycemia might have a different chronic effect on retinal vascular reactivity and 
inflammatory and endothelial activity. This question is particularly important in the light of previous 
studies showing an impaired vascular reactivity following administration of high doses of glucose (4). 
Intervention and longer longitudinal studies that track changes in vascular inflammatory and 
endothelial function levels and VR are necessary to better determine their association. A fuller 
understanding of biochemical influences to the vascular reactivity response can be obtained by 
measuring certain derived endothelium derived vasoactive factors such as nitric oxide (NO) and 
endothelin-1 (ET-1). We suspect that vascular inflammatory activity may influence endothelium 
derived vasoactive factors, thereby affecting the VR response. Recently, it has been shown that 
vascular adhesion protein-1 (VAP-1) is involved in leukocyte trafficking in inflammatory conditions 
such as endotoxin-induced uveitis. This molecule expressed on the endothelium of retinal vessels is 
known to contribute to inflammatory leukocyte recruitment and angiogenesis in experimental models 
of ocular diseases. However, further studies are needed to address the expression and function of 








Isolating Markers of Inflammation (sICAM-1, sVCAM-1, and E-selectin) 
The assays are based on the standard ELISA sandwich enzyme immunoassay technique. For each 
type of assay, monoclonal antibodies (sICAM-1, sVCAM-1 or sE-selectin) are pre-coated onto the 
microplates. Standards, samples, conjugates and controls are pipetted into the wells and then 
incubated for 1.5 hrs at room temperature. Any adhesion molecules present (sICAM-1, sVCAM-1 or 
sE-selectin) is sandwiched by the immobilized antibody and the enzyme-linked monoclonal antibody 
specific for that adhesion molecule. The microplates are then aspirated and then washed with a buffer 
solution (buffered surfactants with preservatives) four times so that any unbound antibody-enzyme 
conjugates are removed. The microplate is then inverted to remove any excess buffer solution. 
Immediately following the buffer wash, the substrate solution (a prepared solution of hydrogen 
peroxide and chromogen) are added to the wells and incubated for 20 minutes, away from light. 
Chromogen changes colour when cleaved by the enzyme attached to the second antibody. A stop 
solution of sulfuric acid is then added to each well to terminate further changes in colour. Optical 
density (OD) is determined for each well using a microplate set to 450nm using Spectral Max Plus 
384 (Softmaxpro). 
Isolating a marker of endothelial dysfunction, vWF antigen 
The STA Liatest vWF kit involves the measurement of monochromatic light traversing a suspension 
of microlatex particles to which polyclonal rabbit antihuman vWF antibodies have been attached by 
covalent bonding. Where the wavelength of the light is much greater than the diameter of the latex 
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particles, the light is only slightly absorbed. In the presence of the antigen under test, the antibody-
coated latex particles agglutinate to form aggregates of diameters greater than the wavelength of the 
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